Biological Functions of Fatty Acids
1. Introduction
Fatty acids are far more than simple building blocks of adipose tissue or inert sources of metabolic fuel. They are dynamic, multifunctional molecules that play essential roles in virtually every aspect of cellular life. From determining the physical properties of cell membranes to orchestrating complex signalling networks, fatty acids actively participate in maintaining homeostasis, regulating gene expression, and mediating communication between cells and tissues. Understanding their biological functions is therefore fundamental to the science of nutrition and cellular physiology (Djuricic & Calder 2021).
In humans and other animals, fatty acids cannot be viewed merely as dietary fat; they are integral components of phospholipids that form the bilayer of all cell membranes. The specific fatty acid composition of membrane phospholipids – whether saturated, monounsaturated, or polyunsaturated – directly influences membrane fluidity, flexibility, and the function of membrane-bound proteins such as receptors, ion channels, and transporters (Djuricic & Calder 2021; Calder 2017). Among the most biologically significant are the polyunsaturated fatty acids (PUFAs) of the omega-6 and omega-3 families. Linoleic acid (LA, 18:2n-6) and α-linolenic acid (ALA, 18:3n-3) are classified as essential fatty acids because they cannot be synthesised de novo by the human body and must be obtained from the diet (Saini & Keum 2018; Shahidi & Ambigaipalan 2018).
Once ingested, LA and ALA can be converted through a shared enzymatic pathway involving desaturases (FADS1, FADS2) and elongases (ELOVL) into longer-chain, more unsaturated derivatives. Linoleic acid gives rise to arachidonic acid (ARA, 20:4n-6), while α-linolenic acid is converted to eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) (Djuricic & Calder 2022; Saini & Keum 2018). This biosynthetic pathway is subject to competition between omega-6 and omega-3 substrates, a fact that has profound implications for the types of bioactive mediators produced in cells (Simopoulos 2016; Wu, Xu & Ballantyne 2019).
One of the most extensively studied biological functions of fatty acids is their role as precursors of lipid mediators. Arachidonic acid, which is typically the most abundant PUFA in the membranes of immune and inflammatory cells, serves as the substrate for cyclooxygenases (COX), lipoxygenases (LOX), and cytochrome P450 enzymes to produce eicosanoids – including prostaglandins, leukotrienes and thromboxanes (Innes & Calder 2018; Calder 2017). These molecules are potent local signals that regulate processes ranging from vascular tone to platelet aggregation and leukocyte recruitment. Importantly, the eicosanoids derived from arachidonic acid generally possess high biological potency, whereas those derived from EPA are often less potent or have distinct activities (Innes & Calder 2018).
A landmark advance in the field has been the discovery that EPA and DHA are also precursors of a distinct family of pro-resolving mediators, collectively known as specialised pro-resolving mediators (SPMs). These include resolvins (E-series from EPA, D-series from DHA), protectins (also called neuroprotectins when produced in neural tissue), and maresins (Ishihara, Yoshida & Arita 2019; Calder 2017). Unlike the classic pro-inflammatory eicosanoids, SPMs actively promote the resolution of inflammation by limiting neutrophil infiltration, stimulating macrophage phagocytosis of apoptotic cells (efferocytosis), and restoring tissue homeostasis (Ishihara et al. 2019). Their discovery has transformed our understanding of inflammation from a self-limiting process that merely “fades away” to an actively regulated programme of resolution.
Beyond these oxidised derivatives, free fatty acids themselves can act as signalling molecules through specific G protein-coupled receptors (GPCRs). For example, long-chain PUFAs activate GPR40 (FFAR1) and GPR120 (FFAR4), while short-chain fatty acids (SCFAs) – acetate, propionate and butyrate – produced by gut bacterial fermentation of dietary fibre bind to GPR41 (FFAR3) and GPR43 (FFAR2) (Birkeland et al. 2023; Ney et al. 2023). These receptor systems link fatty acid sensing to the secretion of gut hormones, modulation of immune cell function, and regulation of energy metabolism.
Short-chain fatty acids deserve special attention as a bridge between the gut microbiota and host physiology. Butyrate, in particular, serves as the primary energy source for colonocytes and helps maintain intestinal barrier integrity by regulating the expression of tight junction proteins (Ney et al. 2023). Propionate and acetate, meanwhile, influence gluconeogenesis and lipid metabolism. Through these actions, SCFA contribute to the maintenance of gut homeostasis and the regulation of systemic metabolic pathways (Birkeland et al. 2023; Ney et al. 2023).
Fatty acids also act directly at the nuclear level. Polyunsaturated fatty acids and their metabolites are natural ligands for peroxisome proliferator-activated receptors (PPARs) – PPARα, PPARγ and PPARδ – which are transcription factors that control the expression of numerous genes involved in lipid and carbohydrate metabolism, adipocyte differentiation, and inflammatory responses (Calder 2017; Djuricic & Calder 2022). Through PPAR activation, fatty acids can influence whole-body energy homeostasis without the need for conversion to eicosanoids or SPMs.
In specific tissues, certain fatty acids exhibit unique functions that cannot be replaced by others. DHA is highly enriched in the grey matter of the brain and in retinal photoreceptors, where it contributes to synaptic plasticity, neurotransmission, and visual signalling (Saini & Keum 2018; Shahidi & Ambigaipalan 2018). Linoleic acid has a specialised structural role in the skin, where it is an essential constituent of ceramides that form the epidermal permeability barrier (Djuricic & Calder 2021). Moreover, emerging evidence indicates that dietary PUFAs can modulate the composition and metabolic activity of the gut microbiota, an effect that may contribute to their broader physiological impact (Birkeland et al. 2023; Ney et al. 2023).
Finally, fatty acids are intimately involved in cellular energy metabolism. Their mitochondrial β-oxidation provides a major source of ATP, particularly in tissues such as heart, liver and skeletal muscle. The composition of fatty acids, especially the incorporation of PUFAs into cardiolipins – phospholipids unique to the inner mitochondrial membrane – can influence the efficiency of oxidative phosphorylation and the production of reactive oxygen species (Berkowitz et al. 2026; Ali et al. 2024).
Thus, the biological functions of fatty acids encompass structural, metabolic, and signalling roles that are essential for normal physiology. This article will explore these functions in detail, drawing on contemporary research to provide an educational overview of how fatty acids – from short-chain bacterial products to long-chain polyunsaturated molecules – act as key regulators of cell behaviour and tissue homeostasis. The focus remains on fundamental mechanisms and cellular processes, without extending into clinical recommendations or therapeutic applications.
2. Fatty Acids as Structural Components of Biological Membranes
One of the most fundamental biological functions of fatty acids is their role as structural building blocks of cellular membranes. Virtually all fatty acids in the body are not found free in the cytosol; rather, they are esterified into more complex lipids, most notably phospholipids, which form the bilayer matrix of all cell membranes (Djuricic & Calder 2021; Calder 2017).
Phospholipids consist of a hydrophilic head group attached to a glycerol backbone, with two fatty acid chains linked at the sn-1 and sn-2 positions. The fatty acid at the sn-2 position is almost always unsaturated, and in the membranes of many cell types involved in immune and inflammatory responses, this position is preferentially occupied by arachidonic acid (ARA, 20:4n-6) (Innes & Calder 2018; Djuricic & Calder 2021). The specific fatty acid composition of membrane phospholipids is not random; it is dynamically regulated by diet, by the activity of enzymes that remodel membrane lipids (such as acyltransferases and phospholipases), and by the availability of different fatty acids from the extracellular environment (Calder 2017).
2.1. Influence on Membrane Physical Properties
The length and degree of unsaturation of fatty acid chains have profound effects on the biophysical properties of the lipid bilayer. Saturated fatty acids (with no double bonds) pack tightly together, increasing membrane rigidity and reducing fluidity. In contrast, unsaturated fatty acids contain cis-double bonds that introduce kinks in the hydrocarbon chains, preventing close packing and thereby increasing membrane fluidity and flexibility (Djuricic & Calder 2021; Saini & Keum 2018).
Polyunsaturated fatty acids (PUFAs), with two or more double bonds, have an even more pronounced fluidising effect. Docosahexaenoic acid (DHA, 22:6n-3), which contains six double bonds, imparts exceptional conformational flexibility to membranes. This property is particularly important in tissues such as the brain and retina, where DHA is highly enriched (Saini & Keum 2018; Shahidi & Ambigaipalan 2018). Membrane fluidity, in turn, influences the lateral mobility and rotational freedom of membrane proteins, including receptors, ion channels and transporters, thereby modulating their functional activity (Calder 2017).
2.2. Lipid Rafts and Signalling Compartments
Biological membranes are not homogenous fluids; they contain specialised microdomains known as lipid rafts. These are dynamic, nanoscale assemblies enriched in cholesterol, sphingolipids, and specific types of phospholipids that exist in a more ordered state than the surrounding bilayer (Calder 2017; Wu, Xu & Ballantyne 2019). Lipid rafts serve as platforms for the clustering and activation of signalling proteins, including Toll-like receptors (TLRs), T-cell receptors and various kinases.
The fatty acid composition of membrane phospholipids strongly influences the formation and stability of lipid rafts. Saturated fatty acids and long-chain saturated acyl chains favour raft formation because they pack tightly together. In contrast, incorporation of PUFAs such as EPA and DHA disrupts raft integrity by increasing membrane fluidity and reducing the ordering of lipids (Calder 2017; Wu et al. 2019). This disruption can prevent the recruitment of signalling proteins into rafts, thereby modulating cellular responses to external stimuli. For example, DHA has been shown to inhibit the lipopolysaccharide (LPS)-induced recruitment of the signalling adaptor protein MyD88 into lipid rafts in macrophages, an effect that reduces subsequent activation of the pro-inflammatory transcription factor NF-κB (Calder 2017).
2.3. Differential Distribution of Fatty Acids Among Cell Types
Different cell types display characteristic fatty acid profiles that reflect their specific functions. In humans consuming a typical Western diet, peripheral blood mononuclear cells (lymphocytes and monocytes) contain a mean arachidonic acid (ARA) content of approximately 15–20% of total fatty acids, while linoleic acid (LA) is present at about 10% and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at much lower levels (typically < 1% and 2–3%, respectively) (Innes & Calder 2018). Neutrophils have a similar ARA content, often around 9–15% of total fatty acids (Innes & Calder 2018).
This high ARA content is of physiological significance because ARA is the primary substrate for the production of eicosanoids – prostaglandins, leukotrienes and thromboxanes – that regulate immune and inflammatory processes (Innes & Calder 2018; Calder 2017). The preferential enrichment of immune cells with ARA reflects both dietary availability (ARA is found in meat, eggs and organ meats) and the activity of metabolic pathways that convert linoleic acid to ARA within the body (Djuricic & Calder 2021).
In sharp contrast, the nervous system and the retina have a unique fatty acid composition dominated by DHA. DHA constitutes up to 40% of total fatty acids in the grey matter of the brain and a similar proportion in retinal photoreceptor membranes (Saini & Keum 2018; Shahidi & Ambigaipalan 2018). This remarkable enrichment is not accidental; DHA confers specific biophysical properties that are essential for synaptic transmission, neuronal plasticity, and the kinetics of the visual pigment rhodopsin (Djuricic & Calder 2021; Saini & Keum 2018). The retina, for example, contains specialised membranes rich in DHA that undergo rapid conformational changes upon light exposure, a process that is fundamental to phototransduction (Shahidi & Ambigaipalan 2018).
2.4. Fatty Acid Remodelling and Functional Adaptation
Cells possess enzymatic machinery to remodel their membrane fatty acid composition in response to changes in dietary intake or metabolic demand. When humans increase their intake of EPA and DHA, for instance through fish oil consumption, these long-chain PUFAs are readily incorporated into the phospholipids of peripheral blood mononuclear cells, neutrophils, and other cell types, partly at the expense of ARA (Calder 2017; Djuricic & Calder 2021). This incorporation occurs in a time- and dose-dependent manner (Calder 2017). Such remodelling is functionally significant because it alters the substrate pool for eicosanoid synthesis and influences signalling pathways that depend on lipid raft integrity.
Thus, the structural role of fatty acids in biological membranes is not a passive one. By determining membrane fluidity, organising signalling platforms, and providing a reservoir for bioactive mediator production, the fatty acid composition of membrane phospholipids actively shapes cellular function. This principle – that the identity of the fatty acids incorporated into membranes has direct consequences for cell behaviour – lies at the heart of understanding the biological functions of these molecules.
3. Fatty Acid Metabolism: From Precursors to Bioactive Forms
The biological functions of fatty acids depend not only on their dietary intake but also on their enzymatic conversion within the body. While humans can synthesise saturated and monounsaturated fatty acids from acetyl-CoA, we lack the enzymes to introduce double bonds at the Δ12 and Δ15 positions (counting from the carboxyl end). Consequently, linoleic acid (LA, 18:2n-6) and α-linolenic acid (ALA, 18:3n-3) are classified as essential fatty acids that must be obtained from the diet (Djuricic & Calder 2021; Saini & Keum 2018). Once ingested, these 18‑carbon precursors can be metabolised through a common pathway to generate longer‑chain, more highly unsaturated polyunsaturated fatty acids (PUFAs) that serve both structural and signalling functions.
3.1. The Desaturation–Elongation Pathway
Pathway of conversion of essential fatty acids to their more unsaturated and longer chain derivatives
This figure illustrates the sequential desaturation (by Δ6- and Δ5-desaturases) and elongation steps that convert the essential 18‑carbon precursors linoleic acid (LA, 18:2n-6) and α-linolenic acid (ALA, 18:3n-3) into longer-chain polyunsaturated fatty acids (arachidonic acid, ARA, 20:4n-6; eicosapentaenoic acid, EPA, 20:5n-3; and docosahexaenoic acid, DHA, 22:6n-3). The shared use of the same enzymes creates competition between the omega‑6 and omega‑3 families (Djuricic & Calder 2021, Figure 3). CC BY 4.0
The conversion of LA and ALA to their respective long‑chain derivatives occurs primarily in the liver and involves four families of enzymes: Δ6‑desaturase (encoded by FADS2), Δ5‑desaturase (encoded by FADS1), elongases (mainly ELOVL2 and ELOVL5), and, for the final step of docosahexaenoic acid (DHA) synthesis, a peroxisomal β‑oxidation step (Djuricic & Calder 2022; Saini & Keum 2018; Shahidi & Ambigaipalan 2018).
Linoleic acid (18:2n-6) is first desaturated by Δ6‑desaturase to γ‑linolenic acid (GLA, 18:3n-6). GLA is then elongated by elongase 5 to dihomo‑γ‑linolenic acid (DGLA, 20:3n-6), which in turn is desaturated by Δ5‑desaturase to arachidonic acid (ARA, 20:4n-6). The same series of reactions acts on α‑linolenic acid (18:3n-3): Δ6‑desaturation yields stearidonic acid (18:4n-3), elongation produces eicosatetraenoic acid (20:4n-3), and Δ5‑desaturation generates eicosapentaenoic acid (EPA, 20:5n-3) (Saini & Keum 2018; Simopoulos 2016).
The synthesis of DHA (22:6n-3) from EPA is more complex and involves two additional elongation steps, a second Δ6‑desaturation, and a peroxisomal chain‑shortening reaction (the “Sprecher pathway”). Specifically, EPA is elongated twice to 24:5n-3, then desaturated by Δ6‑desaturase to 24:6n-3, which is finally transported to peroxisomes where one cycle of β‑oxidation removes two carbons to produce DHA (Saini & Keum 2018; Shahidi & Ambigaipalan 2018). A similar pathway operates for the conversion of ARA to docosapentaenoic acid (DPA, 22:5n-6) and then to 22:6n-6 (osbond acid), although this route is quantitatively less significant in humans.
3.2. Competition Between Omega‑6 and Omega‑3 Substrates
The desaturation and elongation enzymes are shared between the omega‑6 and omega‑3 families. Δ6‑desaturase, the rate‑limiting enzyme in this pathway, has a higher affinity for α‑linolenic acid than for linoleic acid (Simopoulos 2016; Saini & Keum 2018). However, because linoleic acid is typically consumed in much larger quantities (the ratio of LA to ALA in Western diets is often 10:1 or higher), the net flux through the pathway predominantly favours the conversion of LA to ARA (Djuricic & Calder 2021; Djuricic & Calder 2022). Consequently, tissue levels of arachidonic acid are generally high, while EPA and DHA levels are relatively low unless they are supplied directly through the diet (e.g., from fatty fish or fish oil supplements) (Innes & Calder 2018; Calder 2017).
This competition has important consequences for the production of bioactive lipid mediators. A high intake of linoleic acid can reduce the conversion of α‑linolenic acid to EPA and DHA, an effect that may limit the availability of these omega‑3 substrates for the synthesis of anti‑inflammatory and pro‑resolving mediators (Simopoulos 2016; Djuricic & Calder 2022). Conversely, increasing the dietary supply of EPA and DHA not only elevates their tissue levels directly but also partially suppresses the conversion of LA to ARA, thereby reducing the arachidonic acid content of cell membranes (Calder 2017; Djuricic & Calder 2021).
3.3. Limited Conversion of ALA to EPA and DHA in Humans
Numerous human studies have demonstrated that the conversion of α‑linolenic acid to EPA and, especially, to DHA is very inefficient. Estimates from stable isotope tracer studies indicate that only about 5–10% of ALA is converted to EPA, and less than 1% is converted to DHA (Saini & Keum 2018; Shahidi & Ambigaipalan 2018). Women appear to have somewhat higher conversion rates than men, possibly due to the influence of oestrogen on desaturase activity (Simopoulos 2016). Nevertheless, the overall efficiency is so low that plant‑based sources of ALA (e.g., flaxseed, walnuts, canola oil) cannot reliably maintain adequate DHA status in humans unless preformed DHA is also consumed (Djuricic & Calder 2021; Djuricic & Calder 2022).
This limited conversion explains why populations that do not consume marine foods often have very low circulating and tissue levels of EPA and DHA. It also underscores why long‑chain omega‑3 PUFAs are considered conditionally essential nutrients: under typical dietary conditions, endogenous synthesis from ALA is insufficient to meet the body’s physiological demands, particularly for neural and retinal functions (Shahidi & Ambigaipalan 2018; Saini & Keum 2018).
3.4. Regulation of Desaturase Activity
The activity of Δ6‑desaturase and Δ5‑desaturase is not fixed; it is influenced by hormonal signals, nutritional status, and genetic variation. Insulin upregulates desaturase expression, while glucagon and catecholamines have the opposite effect. Deficiencies of certain micronutrients—particularly zinc, magnesium, and vitamin B6—can impair desaturase activity (Simopoulos 2016; Saini & Keum 2018). Furthermore, polymorphisms in the FADS1 and FADS2 genes are associated with significant inter‑individual differences in the capacity to convert LA to ARA and ALA to EPA. Some haplotypes are linked to higher levels of arachidonic acid and lower levels of EPA and DHA in plasma and cell membranes, which may influence the balance of downstream eicosanoid and SPM production (Wu, Xu & Ballantyne 2019; Djuricic & Calder 2022).
3.5. Compartmentalisation of Fatty Acid Metabolism
Fatty acid metabolism is highly compartmentalised within the cell. Desaturation and elongation occur on the endoplasmic reticulum, while β‑oxidation takes place in mitochondria and peroxisomes. The final step of DHA synthesis requires the transport of 24:6n-3 from the endoplasmic reticulum to peroxisomes, where chain shortening occurs (Saini & Keum 2018). This spatial separation allows cells to regulate the flux of intermediates and to direct newly synthesised long‑chain PUFAs towards specific fates: incorporation into membrane phospholipids, esterification into triacylglycerols for storage, or conversion into bioactive lipid mediators.
Once incorporated into membrane phospholipids, arachidonic acid, EPA, and DHA can be released by the action of phospholipase A2 enzymes upon cellular activation. This release is a critical control point for the production of eicosanoids and specialised pro‑resolving mediators (SPMs), which will be discussed in the following sections (Calder 2017; Innes & Calder 2018). Thus, the metabolic pathway from dietary essential fatty acids to membrane‑bound precursors and, ultimately, to signalling molecules represents an elegant link between nutrition and cell function.
4. Signalling Functions: Eicosanoids and Oxylipins
Beyond their structural roles in membranes, polyunsaturated fatty acids (PUFAs) serve as the primary precursors for a vast array of bioactive lipid mediators that regulate cellular communication, vascular tone, platelet aggregation, and the inflammatory response. Two major classes of such mediators are eicosanoids (derived mainly from 20‑carbon PUFAs) and the broader family of oxylipins (oxygenated metabolites of both 18‑carbon and 20‑carbon PUFAs). The production of these signalling molecules is tightly controlled and occurs largely upon cell activation, allowing fatty acids to act as dynamic regulators of physiology (Calder 2017; Innes & Calder 2018).
4.1. Release of Arachidonic Acid by Phospholipase A2
In resting cells, arachidonic acid (ARA, 20:4n-6) is esterified almost exclusively at the sn-2 position of membrane phospholipids, particularly phosphatidylcholine and phosphatidylethanolamine. In this esterified form, ARA is metabolically inert and does not participate in signalling. Upon exposure to extracellular stimuli—such as bacterial lipopolysaccharide (LPS), cytokines, or physical injury—calcium‑dependent cytosolic phospholipase A2 (cPLA2) is activated and translocates to the membrane, where it hydrolyses the sn-2 ester bond, releasing free ARA into the cytosol (Innes & Calder 2018; Calder 2017).
The amount of free ARA released is normally kept low because cells possess efficient reacylation mechanisms that rapidly re‑esterify ARA back into membrane phospholipids. However, under sustained stimulation, the balance shifts, and free ARA accumulates, becoming available for oxidative metabolism (Innes & Calder 2018). This tightly regulated release is the first committed step in eicosanoid biosynthesis.
4.2. Enzymatic Pathways: Cyclooxygenases, Lipoxygenases and Cytochrome P450
Oxidative metabolism of arachidonic acid (AA) and eicosapentaenoic acid (EPA) by the cyclooxygenase and 5-lipoxygenase pathways
This scheme shows how both AA (an omega‑6 fatty acid) and EPA (an omega‑3 fatty acid) are metabolised by cyclooxygenase (COX) and 5‑lipoxygenase (5‑LOX). The products – prostaglandins, thromboxanes and leukotrienes – differ in structure and biological potency. EPA‑derived eicosanoids (e.g., LTB5, TXA₃, PGE₃) are generally less active than their AA‑derived counterparts (Simopoulos 2016, Figure 2). CC BY 4.0
Once released, arachidonic acid can be metabolised by three main families of oxygenases:
- Cyclooxygenases (COX-1 and COX-2) – These enzymes convert ARA to prostaglandin H2 (PGH2), the common precursor of all prostanoids. COX-1 is constitutively expressed in most tissues and is responsible for basal production of prostanoids involved in homeostasis (e.g., gastric mucosal protection, platelet function). COX-2 is induced by inflammatory stimuli and is the major source of pro‑inflammatory prostanoids (Innes & Calder 2018; Calder 2017).
- Lipoxygenases (5-LOX, 12-LOX, 15-LOX) – These enzymes insert molecular oxygen at specific positions of the arachidonic acid backbone. 5‑LOX, primarily expressed in leukocytes, generates leukotrienes and lipoxins. 12‑LOX and 15‑LOX produce hydroxyeicosatetraenoic acids (HETEs) and also participate in the synthesis of lipoxins and specialised pro‑resolving mediators (Innes & Calder 2018; Ishihara, Yoshida & Arita 2019).
- Cytochrome P450 (CYP) monooxygenases – CYP enzymes catalyse two types of reactions on ARA: epoxygenation (producing epoxyeicosatrienoic acids, EETs) and ω‑hydroxylation (producing HETEs). EETs have vasodilatory and anti‑inflammatory properties, while ω‑HETEs are generally vasoconstrictive (Innes & Calder 2018; Berkowitz et al. 2026).
Analogous pathways also operate on other PUFAs, including dihomo‑γ‑linolenic acid (DGLA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), giving rise to distinct families of mediators (Saini & Keum 2018; Shahidi & Ambigaipalan 2018).
4.3. Major Classes of Eicosanoids from Arachidonic Acid
The term “eicosanoid” encompasses all oxygenated metabolites of 20‑carbon PUFAs. From arachidonic acid, three main classes are produced:
- Prostaglandins (PGs) – Synthesised via the COX pathway, prostaglandins are designated by letters (PGA, PGE, PGF, PGI) and subscripts (e.g., PGE2) indicating the number of double bonds. PGI₂ (prostacyclin) is produced mainly by endothelial cells; it is a vasodilator and inhibits platelet aggregation. TXA2 (thromboxane A2) is produced by platelets; it is a vasoconstrictor and promotes platelet aggregation. PGE2 is a potent mediator of fever, pain, and vasodilation, and it synergises with other inflammatory signals (Innes & Calder 2018; Calder 2017).
- Leukotrienes (LTs) – Synthesised via the 5‑LOX pathway, leukotrienes are designated with letters (LTA, LTB, LTC, LTD, LTE) and subscripts. LTB4 is a powerful chemoattractant for neutrophils and promotes leukocyte adhesion and degranulation. The cysteinyl leukotrienes LTC₄, LTD₄ and LTE₄ cause bronchoconstriction and increase vascular permeability, playing key roles in asthma and allergic reactions (Innes & Calder 2018).
- Lipoxins (LXs) – Also derived from ARA via transcellular metabolism involving 5‑LOX and 12/15‑LOX, lipoxins (LXA₄ and LXB4) are unique because they possess anti‑inflammatory and pro‑resolving activities. They inhibit neutrophil recruitment, stimulate macrophage phagocytosis of apoptotic cells, and promote the resolution of inflammation (Innes & Calder 2018; Ishihara et al. 2019).
These eicosanoids act through specific G protein‑coupled receptors expressed on target cells, and their effects are generally local and short‑lived due to rapid enzymatic degradation (Innes & Calder 2018).
4.4. Comparison of Eicosanoids Derived from ARA and EPA
Eicosapentaenoic acid (EPA, 20:5n-3) is also a substrate for COX and LOX enzymes, but the mediators produced differ structurally from those derived from ARA. For example, EPA gives rise to 3‑series prostaglandins (PGE₃) and 5‑series leukotrienes (LTB5). These EPA‑derived eicosanoids are typically less potent than their ARA‑derived counterparts. LTB5, for instance, is 10–100 times less active as a neutrophil chemoattractant than LTB4, and TXA₃ is a weaker vasoconstrictor and platelet aggregator than TXA2 (Calder 2017; Innes & Calder 2018).
Because EPA and ARA compete for the same COX and LOX enzymes, increasing the cellular content of EPA (e.g., through dietary fish oil) leads to reduced production of ARA‑derived pro‑inflammatory eicosanoids and increased production of less potent EPA‑derived mediators. This shift in eicosanoid profile is one of the key mechanisms by which omega‑3 PUFAs modulate inflammatory responses without completely blocking the pathway (Calder 2017; Djuricic & Calder 2021).
Furthermore, EPA and DHA are precursors for specialised pro‑resolving mediators (resolvins, protectins, maresins), which will be discussed in Section 5, whereas ARA gives rise to lipoxins that also contribute to resolution (Ishihara et al. 2019; Calder 2017). Thus, both PUFA families contribute to the active termination of inflammation, although through different mediator profiles.
4.5. Oxylipins Derived from Linoleic Acid
Linoleic acid (LA, 18:2n-6) is the most abundant PUFA in the human diet and in many tissues. It can be oxidised by lipoxygenases and cytochrome P450 enzymes to produce a family of oxylipins known as oxidised linoleic acid metabolites (OXLAMs). Key members include:
- 9‑Hydroxyoctadecadienoic acid (9‑HODE) and 13‑HODE – These are produced by 15‑LOX and, to a lesser extent, by non‑enzymatic oxidation. 13‑HODE has been shown to activate peroxisome proliferator‑activated receptor γ (PPARγ) and may exert anti‑inflammatory and insulin‑sensitising effects. In vascular biology, 13‑HODE is associated with anti‑atherogenic actions, including reduced endothelial adhesion. In contrast, 9‑HODE has been linked to vascular injury and inflammation (Berkowitz et al. 2026; Innes & Calder 2018).
- Epoxyoctadecenoic acids (EpOMEs) and dihydroxyoctadecenoic acids (DiHOMEs) – EpOMEs are generated by CYP epoxygenases and can be further hydrolysed by soluble epoxide hydrolase (sEH) to DiHOMEs. While EpOMEs may have protective roles in certain contexts, their conversion to DiHOMEs is generally associated with cytotoxic and pro‑inflammatory effects, particularly in the lung and cardiovascular system. However, 12,13‑DiHOME has emerged as a beneficial lipokine that enhances fatty acid uptake and oxidation in brown adipose tissue and skeletal muscle during cold exposure and exercise, improving metabolic flexibility (Berkowitz et al. 2026; Ney et al. 2023).
The balance between different LA‑derived oxylipins depends on the prevailing oxidative state, the activity of specific enzymes (including sEH), and the concurrent presence of other PUFAs that may compete for the same oxygenases. This complexity means that the biological effects of dietary LA cannot be inferred from its simple precursor role; rather, they depend on the local metabolic context (Berkowitz et al. 2026).
4.6. Physiological Significance of Eicosanoid and Oxylipin Signalling
Eicosanoids and oxylipins are not merely by‑products of fatty acid metabolism; they are essential mediators of homeostasis. Under resting conditions, low levels of these mediators contribute to the maintenance of vascular tone, renal blood flow, gastric mucosal integrity, and platelet homeostasis (Innes & Calder 2018). During infection or injury, their production increases dramatically, orchestrating the classic signs of inflammation: redness, swelling, heat, and pain. Once the threat is eliminated, the same pathway can generate pro‑resolving mediators (lipoxins from ARA; resolvins, protectins and maresins from EPA/DHA) that actively terminate the inflammatory response and promote tissue repair (Ishihara et al. 2019; Calder 2017).
Thus, the signalling functions of fatty acids represent a continuum from initiation to resolution. The specific profile of mediators produced depends on the fatty acid composition of membrane phospholipids, the activity of the oxygenase enzymes, and the cellular context. This intricate system allows the body to mount appropriate responses to challenges while preventing excessive or prolonged inflammation that could damage host tissues.
5. Specialised Pro-Resolving Mediators (SPMs) from Omega-3 Fatty Acids
One of the most significant advances in our understanding of the biological functions of polyunsaturated fatty acids has been the discovery that eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are precursors for a distinct family of bioactive lipid mediators that actively promote the resolution of inflammation. These compounds are collectively known as specialised pro-resolving mediators (SPMs) and include resolvins, protectins and maresins (Ishihara, Yoshida & Arita 2019; Calder 2017). The discovery of SPMs overturned the long‑held view that inflammation resolves passively simply because the initial pro‑inflammatory signals subside. Instead, resolution is now recognised as an actively programmed process involving specific mediators, receptors and cellular responses (Ishihara et al. 2019).
5.1. Discovery of Resolvins, Protectins and Maresins
The SPM family was first identified in the early 2000s by Charles Serhan and colleagues using liquid chromatography‑tandem mass spectrometry (LC‑MS/MS)-based lipidomics. By analysing inflammatory exudates from resolving inflammation, they detected novel lipid mediators derived from EPA and DHA that possessed potent anti‑inflammatory and pro‑resolving activities (Ishihara et al. 2019).
- Resolvins – Derived from EPA (E‑series resolvins: RvE1, RvE2, RvE3) and from DHA (D‑series resolvins: RvD1 to RvD6). The name “resolvin” reflects their ability to resolve inflammation (Ishihara et al. 2019; Calder 2017).
- Protectins – Derived from DHA (protectin D1, also called neuroprotectin D1 when produced in neural tissue, and protectin DX). These mediators have potent neuroprotective and anti‑inflammatory actions (Ishihara et al. 2019; Saini & Keum 2018).
- Maresins – Also derived from DHA (maresin 1 and maresin 2). The name “maresin” stands for “macrophage mediator in resolving inflammation” (Ishihara et al. 2019; Calder 2017).
More recently, analogous SPMs have been identified from docosapentaenoic acid (DPA, 22:5n-3), the third major marine‑derived omega‑3 PUFA (Ishihara et al. 2019). Additionally, sulphide‑conjugated forms of these mediators – termed resolvin conjugates in tissue regeneration (RCTRs), protectin conjugates in tissue regeneration (PCTRs) and maresin conjugates in tissue regeneration (MCTRs) – have been discovered. These conjugates promote tissue regeneration in addition to their anti‑inflammatory and pro‑resolving actions (Ishihara et al. 2019).
5.2. Biosynthetic Pathways of SPMs
The biosynthesis of SPMs involves the same families of oxygenating enzymes – cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450 – that produce classical eicosanoids. However, the pathways are often transcellular, meaning that the initial oxygenation occurs in one cell type and subsequent reactions take place in another. This transcellular biosynthesis allows for tight spatial and temporal control of SPM production (Ishihara et al. 2019; Calder 2017).
E‑series resolvins (from EPA): The pathway begins with the oxygenation of EPA at carbon 18 by aspirin‑acetylated COX-2 or by certain cytochrome P450 enzymes, producing 18‑hydroxy‑eicosapentaenoic acid (18‑HEPE). 18‑HEPE is then further metabolised by 5‑LOX to generate the intermediate 5,6‑epoxide, which is subsequently hydrolysed to RvE1. Alternatively, 12/15‑LOX can act on 18‑HEPE to produce RvE3 (Ishihara et al. 2019).
D‑series resolvins and protectins (from DHA): DHA is first oxygenated at carbon 17 by 15‑LOX or aspirin‑acetylated COX-2 to yield 17‑hydroxy‑docosahexaenoic acid (17‑HDHA). 17‑HDHA can then be converted by 5‑LOX to D‑series resolvins (RvD1 to RvD6) via an epoxide intermediate, or by 15‑LOX to protectins (PD1, PDX) via a distinct epoxide intermediate (Ishihara et al. 2019; Calder 2017).
Maresins (from DHA): The maresin pathway begins with 14‑lipoxygenation of DHA by macrophage 12‑LOX, producing 13,14‑epoxy‑maresin. This epoxide can be enzymatically hydrolysed to maresin 1 (MaR1) or conjugated with glutathione to form maresin conjugates in tissue regeneration (MCTRs) (Ishihara et al. 2019).
The production of SPMs can be enhanced by dietary supplementation with EPA and DHA. Animal studies have shown increased SPM levels in tissues following feeding with fish oil, and several human studies have reported elevated concentrations of resolvins, protectins and maresins in blood after supplementation with omega‑3 PUFAs (Calder 2017; Djuricic & Calder 2022).
5.3. Biological Actions of SPMs
SPMs exert their effects at very low concentrations (nanomolar to picomolar ranges) through specific G protein‑coupled receptors expressed on various cell types. Key actions include:
- Limiting neutrophil infiltration – SPMs inhibit the transmigration of polymorphonuclear neutrophils (PMNs) across endothelial layers, thereby reducing the influx of these pro‑inflammatory cells into sites of inflammation. For example, RvE1, RvD1 and PD1 all block neutrophil recruitment in murine models of peritonitis and dermatitis (Ishihara et al. 2019; Calder 2017).
- Stimulating macrophage efferocytosis – Efferocytosis is the phagocytic clearance of apoptotic cells (e.g., spent neutrophils) by macrophages. This process is essential for the resolution of inflammation and for preventing secondary necrosis. SPMs, including RvE1, RvD1, PD1 and MaR1, potently enhance macrophage efferocytosis (Ishihara et al. 2019; Calder 2017).
- Promoting macrophage polarisation towards a pro‑resolving phenotype – SPMs encourage the differentiation of macrophages towards an M2‑like phenotype characterised by the production of anti‑inflammatory cytokines (e.g., IL‑10) and tissue‑repair factors (Ishihara et al. 2019).
- Regulating T cell responses – SPMs modulate adaptive immunity by inhibiting the differentiation of naive T cells into pro‑inflammatory Th1 and Th17 subsets while promoting the generation of regulatory T cells (Tregs). RvD1, RvD2 and MaR1 have all been shown to exert such effects on human CD4⁺ T cells (Ishihara et al. 2019).
- Protecting against tissue damage – Protectins, in particular neuroprotectin D1 (NPD1), have been shown to protect neurons and retinal pigment epithelial cells from oxidative stress‑induced apoptosis. NPD1 also promotes the survival of photoreceptors in models of retinal degeneration (Ishihara et al. 2019; Saini & Keum 2018).
- Promoting tissue regeneration – The sulphide‑conjugated SPMs (RCTRs, PCTRs, MCTRs) have been shown to stimulate tissue regeneration in planaria (a model organism for regeneration) and to promote wound healing, an effect mediated in part through extracellular signal‑regulated kinase (ERK) signalling (Ishihara et al. 2019).
5.4. SPMs in Preclinical Models of Disease
The biological actions of SPMs have been extensively validated in animal models of inflammatory and immune‑mediated diseases. Key observations include:
- Peritonitis – Administration of RvE1 or PD1 in zymosan‑induced sterile peritonitis reduces neutrophil infiltration, promotes macrophage efferocytosis, and accelerates the clearance of inflammatory cells into draining lymph nodes (Ishihara et al. 2019).
- Colitis – RvE1 protects against 2,4,6‑trinitrobenzene sulphonic acid (TNBS)-induced colitis in mice, reducing colonic inflammation and tissue damage (Ishihara et al. 2019).
- Asthma and allergic airway inflammation – RvE1, RvD1 and PD1 dampen airway hyperresponsiveness, reduce eosinophil infiltration and mucus production, and promote the resolution of allergic inflammation in murine models of asthma (Ishihara et al. 2019; Calder 2017).
- Arthritis – RvD1 reduces joint inflammation, cartilage destruction and pain behaviour in models of inflammatory arthritis (Ishihara et al. 2019).
- Myocardial infarction – RvD1 improves ventricular function and reduces post‑infarct remodelling in a mouse model of myocardial infarction, partly by enhancing macrophage efferocytosis and reducing inflammatory cytokine production (Ishihara et al. 2019).
- Sepsis – RvD2 improves survival in a mouse model of polymicrobial sepsis, limiting bacterial dissemination and reducing systemic inflammation (Ishihara et al. 2019).
These preclinical studies demonstrate that SPMs are not merely laboratory curiosities; they are physiologically relevant mediators that actively control the duration and magnitude of inflammatory responses.
5.5. SPMs in Humans
Evidence for SPM production and action in humans is accumulating, although it remains less extensive than the animal data. Several studies have shown that dietary supplementation with fish oil (providing EPA and DHA) increases the levels of resolvins, protectins and maresins in human blood, plasma and cells (Calder 2017; Djuricic & Calder 2022). For example, Mas et al. (2012) demonstrated that supplementation with EPA and DHA raised circulating concentrations of RvD1, RvD2 and other SPMs in healthy volunteers. Similarly, Polus et al. (2016) reported increased SPM levels in the blood of women with obesity following omega‑3 supplementation, accompanied by changes in whole‑blood gene expression consistent with the resolution of inflammation.
In clinical studies, higher blood levels of EPA and DHA (and thus presumably higher SPM synthesis capacity) have been associated with better outcomes in inflammatory conditions such as rheumatoid arthritis, although direct measurements of SPMs in these trials are still limited (Calder 2017). Nonetheless, the existing human data support the concept that the anti‑inflammatory and pro‑resolving effects of omega‑3 PUFAs are mediated, at least in part, through the production of SPMs.
5.6. Integration with Other Fatty Acid Signalling Systems
The SPM pathway does not operate in isolation. It is integrated with other lipid mediator cascades. For instance, the production of lipoxins (from arachidonic acid) also contributes to the resolution of inflammation, and there is evidence for “class switching” during the inflammatory response: early in inflammation, the dominant lipid mediators are pro‑inflammatory eicosanoids (prostaglandins, leukotrienes); as inflammation proceeds, the profile shifts toward lipoxins and SPMs that actively terminate the response (Innes & Calder 2018; Ishihara et al. 2019). This temporal orchestration ensures that inflammation is appropriately initiated and then efficiently resolved.
Thus, SPMs represent a paradigm shift in our understanding of the biological functions of omega‑3 fatty acids. Rather than merely acting as passive membrane components or as weak competitors of arachidonic acid metabolism, EPA and DHA are the biosynthetic precursors of a family of potent mediators that actively control the resolution of inflammation and promote tissue repair. This insight has profound implications for how we view the role of dietary fatty acids in maintaining health.
6. Receptor Mechanisms of Fatty Acid Action
In addition to their roles as structural membrane components and as precursors for bioactive lipid mediators, free fatty acids themselves act directly as signalling molecules by binding to specific cell surface receptors. Most of these receptors belong to the large family of G protein‑coupled receptors (GPCRs). The discovery that fatty acids are natural ligands for several GPCRs has fundamentally expanded our understanding of how dietary fats and microbially derived metabolites can regulate physiology independently of their metabolic or energetic functions (Birkeland et al. 2023; Ney et al. 2023; Calder 2017).
These receptors are expressed on a wide range of cell types, including enteroendocrine cells, adipocytes, pancreatic β‑cells, immune cells, and neurons. They allow cells to sense changes in the concentration of specific fatty acids in the extracellular environment and to initiate appropriate signalling responses. The receptors can be broadly divided into those that recognise short‑chain fatty acids (SCFAs) and those that recognise long‑chain fatty acids, particularly polyunsaturated fatty acids (PUFAs) (Berkowitz et al. 2026; Wu, Xu & Ballantyne 2019).
6.1. Receptors for Short‑Chain Fatty Acids (SCFAs)
Short‑chain fatty acids – primarily acetate (C2), propionate (C3) and butyrate (C4) – are produced in the large intestine by bacterial fermentation of dietary fibre. Their concentrations in the colonic lumen can reach millimolar levels, and they are also detectable in the systemic circulation at lower (micromolar) concentrations. The major receptors for SCFAs are:
- GPR41 (free fatty acid receptor 3, FFAR3) – Activated by propionate > butyrate > acetate. GPR41 is expressed on enteroendocrine L‑cells, adipocytes, sympathetic ganglia, and vascular endothelium. Activation of GPR41 on L‑cells stimulates the release of peptide YY (PYY) and glucagon‑like peptide‑1 (GLP‑1), hormones that regulate appetite and glucose homeostasis (Birkeland et al. 2023; Ney et al. 2023). In adipocytes, GPR41 activation promotes leptin expression.
- GPR43 (free fatty acid receptor 2, FFAR2) – Activated by acetate = propionate > butyrate. GPR43 is highly expressed on immune cells (neutrophils, monocytes, macrophages, dendritic cells) and on enteroendocrine L‑cells and adipocytes. It plays a central role in mediating the anti‑inflammatory effects of SCFAs. For example, activation of GPR43 on neutrophils promotes their chemotaxis towards sites of bacterial infection, while on regulatory T cells (Tregs) it enhances their differentiation and suppressive function. In the gut, GPR43 activation strengthens the intestinal epithelial barrier (Ney et al. 2023; Birkeland et al. 2023).
- GPR109A (hydroxycarboxylic acid receptor 2, HCA2) – Activated by butyrate and also by the pharmacological agent niacin. GPR109A is expressed on colonic epithelial cells, adipose tissue macrophages, and adipocytes. Butyrate acting through GPR109A suppresses colonic inflammation and carcinogenesis by promoting anti‑inflammatory signalling and enhancing IL‑10 production (Ney et al. 2023; Calder 2017).
- Olfr78 (olfactory receptor 78) – Activated by acetate and propionate. This receptor is expressed in the kidney (juxtaglomerular apparatus) and in vascular smooth muscle. It regulates blood pressure by modulating renin secretion and vascular tone. Olfr78 knockout mice are hypotensive, indicating a physiological role for SCFA sensing in cardiovascular regulation (Birkeland et al. 2023; Ney et al. 2023).
Through these receptors, SCFAs influence a broad range of physiological processes, including energy harvest from diet, appetite regulation, insulin secretion, immune homeostasis, and blood pressure control, without being oxidised for ATP production.
6.2. Receptors for Long‑Chain Fatty Acids
Long‑chain fatty acids (including palmitate, oleate, linoleate, α‑linolenate, arachidonate, EPA and DHA) are also sensed by specific GPCRs. The two best‑characterised receptors in this class are:
- GPR40 (free fatty acid receptor 1, FFAR1) – Activated by medium‑ and long‑chain saturated and unsaturated fatty acids. GPR40 is highly expressed on pancreatic β‑cells and on enteroendocrine cells (primarily K and L cells). In β‑cells, fatty acid binding to GPR40 amplifies glucose‑stimulated insulin secretion through a mechanism involving elevation of intracellular calcium. In enteroendocrine cells, GPR40 activation potentiates the secretion of GLP‑1 and glucose‑dependent insulinotropic polypeptide (GIP) (Berkowitz et al. 2026; Wu et al. 2019). Thus, GPR40 links dietary fat intake to the incretin system and to insulin release.
- GPR120 (free fatty acid receptor 4, FFAR4) – Activated by long‑chain unsaturated fatty acids, particularly the omega‑3 PUFAs EPA and DHA. GPR120 is expressed on macrophages, dendritic cells, adipocytes, and enteroendocrine L‑cells. Activation of GPR120 by DHA or EPA exerts potent anti‑inflammatory effects. In macrophages, GPR120 signalling inhibits the activation of the pro‑inflammatory transcription factor NF‑κB and reduces the production of TNF‑α, IL‑6 and other inflammatory cytokines. This effect is mediated through the recruitment of β‑arrestin‑2, which prevents the interaction of the inflammatory signalling complex with downstream effectors (Calder 2017; Berkowitz et al. 2026). In enteroendocrine cells, GPR120 activation also promotes GLP‑1 secretion.
GPR120 has attracted considerable interest because it provides a direct, receptor‑mediated pathway for the anti‑inflammatory actions of omega‑3 PUFAs that is independent of their incorporation into membrane phospholipids or their conversion to eicosanoids and SPMs (Calder 2017; Wu et al. 2019).
6.3. Receptor for Arachidonic Acid Derivatives
In addition to receptors for free fatty acids, many GPCRs recognise eicosanoids and other oxygenated metabolites. For example:
- Prostanoid receptors (DP, EP, FP, IP, TP) – These receptors bind specific prostaglandins and thromboxanes derived from arachidonic acid (Innes & Calder 2018). Each prostanoid has its own primary receptor(s), but there is cross‑reactivity. These receptors regulate platelet aggregation (TP for TXA2, IP for PGI₂), smooth muscle contraction, inflammation, and pain.
- Leukotriene receptors (BLT1, BLT2, CysLT1, CysLT2) – BLT1 is a high‑affinity receptor for LTB4 and mediates neutrophil chemotaxis and adhesion. CysLT receptors bind the cysteinyl leukotrienes LTC₄, LTD₄ and LTE₄ and are involved in bronchoconstriction and vascular permeability (Innes & Calder 2018).
- Receptors for SPMs – Resolvins, protectins and maresins also act through specific GPCRs. For example, RvE1 binds to ChemR23 (also known as chemerin receptor 23) and to BLT1 (as a partial antagonist), while RvD1 binds to GPR32 (in humans) and to ALX/FPR2 (the lipoxin A₄ receptor). These receptor interactions mediate the pro‑resolving actions of SPMs, including the stimulation of macrophage efferocytosis and the inhibition of neutrophil infiltration (Ishihara, Yoshida & Arita 2019; Calder 2017).
6.4. Integration of Receptor‑Mediated Signalling
The existence of multiple fatty acid‑sensitive GPCRs allows cells to discriminate between different fatty acid species and to mount appropriate responses. For example:
- In the gut, SCFAs from bacterial fermentation activate GPR41 and GPR43 on L‑cells, stimulating GLP‑1 and PYY release, which slows gastric emptying and promotes satiety (Birkeland et al. 2023; Ney et al. 2023).
- In pancreatic β‑cells, long‑chain fatty acids activate GPR40, enhancing insulin secretion in response to glucose (Wu et al. 2019).
- In macrophages, DHA and EPA activate GPR120, suppressing NF‑κB and reducing the production of pro‑inflammatory cytokines (Calder 2017; Berkowitz et al. 2026).
- In the kidney, propionate and acetate act on Olfr78 to influence renin release and thus blood pressure regulation (Birkeland et al. 2023).
This receptor‑based sensory system for fatty acids is evolutionarily ancient and complements the slower, genomic actions of fatty acids mediated through nuclear receptors such as PPARs (discussed in Section 7). While PPAR activation regulates gene expression over hours to days, GPCR signalling occurs within seconds to minutes, allowing rapid homeostatic adjustments to changes in nutrient availability or to inflammatory stimuli.
6.5. Clinical and Nutritional Implications of Receptor Signalling
Because GPCRs for fatty acids can be selectively activated by specific dietary fatty acids or by bacterial metabolites, they represent potential targets for nutritional interventions aimed at modulating metabolism and immune function. For instance, diets rich in fermentable fibre increase SCFA production, which through GPR41 and GPR43 improves insulin sensitivity and reduces low‑grade inflammation. Similarly, the beneficial effects of oily fish consumption have been partly attributed to the activation of GPR120 by EPA and DHA (Calder 2017; Birkeland et al. 2023). However, as this review maintains an educational focus, it suffices to note that the receptor mechanisms of fatty acid action provide a direct molecular link between diet and cell function, independent of the classical pathways involving fatty acid oxidation or membrane incorporation.
7. Nuclear Receptors and Transcriptional Regulation
In addition to their rapid actions through membrane‑associated G protein‑coupled receptors, fatty acids also regulate cell function at the genomic level by binding to and activating members of the nuclear receptor superfamily. Nuclear receptors are ligand‑dependent transcription factors that, upon activation, translocate to the nucleus, bind to specific DNA response elements, and modulate the expression of target genes. This mechanism allows fatty acids to exert sustained effects on metabolism, inflammation, and cellular differentiation that typically develop over hours to days (Calder 2017; Djuricic & Calder 2022).
The most extensively studied nuclear receptors for fatty acids are the peroxisome proliferator‑activated receptors (PPARs). Three PPAR isotypes exist in mammals: PPARα (NR1C1), PPARγ (NR1C3), and PPARδ (also called PPARβ; NR1C2). Each isotype has a distinct tissue distribution and regulates specific sets of target genes, but all can be activated by naturally occurring fatty acids and their derivatives (Berkowitz et al. 2026; Wu, Xu & Ballantyne 2019).
7.1. PPARα (Peroxisome Proliferator‑Activated Receptor α)
PPARα is highly expressed in tissues with high rates of fatty acid catabolism, including the liver, heart, skeletal muscle, and kidney. Its primary physiological role is to regulate lipid metabolism, particularly the β‑oxidation of fatty acids.
Ligands for PPARα: Natural ligands include a wide range of saturated and unsaturated fatty acids, as well as eicosanoids such as leukotriene B4 and 8(S)-hydroxyeicosatetraenoic acid (8(S)-HETE). Among dietary fatty acids, the omega‑3 PUFAs EPA and DHA are relatively potent activators of PPARα (Calder 2017; Wu et al. 2019).
Target genes: Upon activation, PPARα increases the transcription of genes encoding enzymes involved in mitochondrial and peroxisomal β‑oxidation (e.g., acyl‑CoA oxidase, carnitine palmitoyltransferase 1, medium‑chain acyl‑CoA dehydrogenase), fatty acid transport proteins (e.g., FAT/CD36), and lipoprotein metabolism (e.g., apolipoprotein A‑I, apolipoprotein A‑II). PPARα also suppresses the expression of acute‑phase proteins and inflammatory genes, contributing to its anti‑inflammatory actions (Calder 2017; Djuricic & Calder 2022).
Physiological consequences: Activation of PPARα by EPA and DHA leads to increased fatty acid oxidation, reduced hepatic triglyceride accumulation, and lowered plasma triglyceride levels. This mechanism is thought to contribute to the hypotriglyceridaemic effect of fish oil. In addition, PPARα activation reduces the expression of pro‑inflammatory cytokines (e.g., IL‑6, TNF‑α) and acute‑phase proteins (e.g., C‑reactive protein) in the liver, an effect that may contribute to the systemic anti‑inflammatory actions of omega‑3 PUFAs (Calder 2017).
7.2. PPARγ (Peroxisome Proliferator‑Activated Receptor γ)
PPARγ is most abundantly expressed in adipose tissue, where it is a master regulator of adipocyte differentiation and lipid storage. It is also present in macrophages, dendritic cells, and colonic epithelial cells, where it modulates immune and inflammatory responses.
Ligands for PPARγ: Natural ligands include polyunsaturated fatty acids (especially EPA and DHA), oxidized fatty acid derivatives (such as 9‑HODE and 13‑HODE derived from linoleic acid), and certain prostaglandins (e.g., 15‑deoxy‑Δ¹²,¹⁴‑PGJ₂). The potency of different fatty acids as PPARγ ligands varies, with long‑chain PUFAs generally being more effective than saturated or monounsaturated fatty acids (Berkowitz et al. 2026; Calder 2017).
Target genes: In adipocytes, PPARγ activates genes involved in fatty acid uptake (FAT/CD36, FATP1), triglyceride synthesis (lipoprotein lipase, acyl‑CoA synthetase), and glucose transport (GLUT4). It also induces the expression of adiponectin, an adipokine with insulin‑sensitising and anti‑inflammatory properties. In macrophages, PPARγ activation suppresses the expression of pro‑inflammatory genes, including inducible nitric oxide synthase (iNOS), cyclooxygenase‑2 (COX‑2), and several interleukins (Berkowitz et al. 2026; Calder 2017).
Physiological consequences: By promoting the differentiation of pre‑adipocytes into mature, insulin‑sensitive adipocytes, PPARγ enhances the body’s capacity to store lipids in subcutaneous adipose tissue, thereby preventing ectopic lipid deposition in the liver, muscle, and pancreas. This improves whole‑body insulin sensitivity. The anti‑inflammatory actions of PPARγ in macrophages contribute to the resolution of adipose tissue inflammation, which is a key feature of metabolic health (Djuricic & Calder 2022; Berkowitz et al. 2026).
Importantly, PPARγ and the pro‑inflammatory transcription factor NF‑κB interact in a mutually antagonistic manner. PPARγ activation can inhibit NF‑κB activity through several mechanisms, including direct protein‑protein interaction (transrepression) and competition for co‑activators. This cross‑talk explains, in part, how fatty acids that activate PPARγ can simultaneously suppress inflammatory gene expression (Calder 2017).
7.3. PPARδ (Peroxisome Proliferator‑Activated Receptor δ)
PPARδ (also called PPARβ) is ubiquitously expressed, with particularly high levels in skeletal muscle, heart, adipose tissue, and keratinocytes. It is involved in fatty acid oxidation, energy expenditure, and the regulation of inflammation.
Ligands for PPARδ: Natural ligands include various fatty acids (especially PUFAs) and eicosanoids such as prostacyclin (PGI₂). EPA and DHA are effective activators of PPARδ (Calder 2017; Wu et al. 2019).
Target genes: PPARδ induces the expression of genes involved in fatty acid oxidation (e.g., carnitine palmitoyltransferase 1, acyl‑CoA oxidase), mitochondrial biogenesis (e.g., PGC‑1α), and energy uncoupling (e.g., UCP‑2, UCP‑3). In macrophages, PPARδ activation reduces inflammation by suppressing the expression of inflammatory chemokines and adhesion molecules.
Physiological consequences: Activation of PPARδ in skeletal muscle and heart increases fatty acid utilisation and enhances exercise capacity. In adipose tissue, PPARδ promotes the “browning” of white adipocytes, increasing thermogenic energy expenditure. These effects may contribute to the metabolic benefits of omega‑3 PUFAs, although the relative contribution of PPARδ compared to PPARα and PPARγ is still under investigation (Djuricic & Calder 2022; Berkowitz et al. 2026).
7.4. Other Nuclear Receptors Affected by Fatty Acids
In addition to the PPAR family, fatty acids and their metabolites can influence the activity of other nuclear receptors:
- Liver X Receptor (LXR) – LXRα is mainly expressed in the liver, while LXRβ is ubiquitous. Both are activated by oxysterols and, to a lesser extent, by certain PUFAs. LXR activation promotes cholesterol efflux from cells by inducing the expression of ABCA1 and ABCG1 transporters. LA has been shown to upregulate LXRα expression in the liver, leading to increased bile acid synthesis and enhanced LDL cholesterol clearance (Djuricic & Calder 2021; Berkowitz et al. 2026).
- Retinoid X Receptor (RXR) – RXR is the obligate heterodimer partner for many nuclear receptors, including PPARs, LXR, and vitamin D receptor. Some polyunsaturated fatty acids have been reported to bind directly to RXR, although their affinity is low compared to the natural ligand 9‑cis‑retinoic acid.
- Hepatocyte Nuclear Factor 4α (HNF4α) – This nuclear receptor regulates the expression of genes involved in glucose and lipid metabolism in the liver and pancreas. Long‑chain fatty acyl‑CoA thioesters, rather than free fatty acids, act as ligands for HNF4α, modulating its transcriptional activity.
7.5. Integration of Nuclear Receptor and Receptor‑Mediated Signalling
The actions of fatty acids on nuclear receptors are typically slower in onset (hours to days) than their actions on GPCRs (seconds to minutes) or their roles as membrane components (continuous). This temporal hierarchy allows cells to integrate rapid nutrient sensing (via GPCRs) with longer‑term adaptive changes in gene expression (via nuclear receptors). For example, after a meal containing EPA and DHA, these fatty acids may rapidly activate GPR120 on enteroendocrine cells to stimulate incretin release (a fast response) and simultaneously enter the cell, be transported to the nucleus, and activate PPARγ and PPARα to increase the expression of genes involved in fatty acid oxidation and insulin sensitivity (a delayed but sustained response) (Calder 2017; Berkowitz et al. 2026).
7.6. Transcriptional Regulation of Inflammation: The NF‑κB and PPAR Interaction
One of the most clinically relevant transcriptional effects of omega‑3 PUFAs is their ability to inhibit the activation of nuclear factor kappa B (NF‑κB). NF‑κB is a pro‑inflammatory transcription factor that controls the expression of many cytokines (e.g., TNF‑α, IL‑1β, IL‑6), adhesion molecules (e.g., ICAM‑1, VCAM‑1), and inducible enzymes (e.g., COX‑2, iNOS). EPA and DHA have been shown to reduce NF‑κB activation in a variety of cell types through multiple mechanisms:
- Disruption of lipid rafts – As discussed in Section 2, incorporation of EPA and DHA into membrane phospholipids disrupts lipid rafts, preventing the assembly of the TLR4 signalling complex and thus reducing NF‑κB activation in response to LPS (Calder 2017).
- Activation of PPARγ – PPARγ activation leads to the sequestration of the NF‑κB subunit p65, reducing its availability to bind to DNA. PPARγ also increases the expression of IκBα, the inhibitory protein that retains NF‑κB in the cytoplasm (Calder 2017; Berkowitz et al. 2026).
- Direct modulation of signalling kinases – EPA and DHA can inhibit the phosphorylation of IκB kinase (IKK) and the subsequent degradation of IκBα, preventing NF‑κB nuclear translocation.
- Activation of GPR120 – As noted in Section 6, GPR120 activation by EPA and DHA recruits β‑arrestin‑2, which interferes with the NF‑κB activation pathway upstream of IKK (Calder 2017).
Through these converging mechanisms, EPA and DHA act as natural inhibitors of NF‑κB, thereby reducing the expression of pro‑inflammatory genes. This transcriptional regulation is a key component of the anti‑inflammatory actions of omega‑3 PUFAs and complements the rapid, receptor‑mediated effects discussed earlier.
7.7. Summary: Fatty Acids as Transcriptional Regulators
Fatty acids are not merely substrates for energy production or structural membrane components; they are also signalling molecules that directly regulate gene expression by activating specific nuclear receptors. The PPAR family of receptors allows cells to sense changes in fatty acid availability and to adjust the expression of genes controlling lipid metabolism, glucose homeostasis, and inflammation accordingly. The ability of EPA and DHA to activate PPARα, PPARγ and PPARδ, and to inhibit NF‑κB, provides a molecular basis for many of the biological functions attributed to these omega‑3 PUFAs. This transcriptional regulatory network operates in concert with the faster membrane receptor systems, enabling the organism to respond to dietary fatty acids at multiple levels of biological organisation.
8. Short‑Chain Fatty Acids (SCFAs): Linking Microbiota and Host
The human gastrointestinal tract harbours a complex and dynamic community of microorganisms — the gut microbiota — that collectively possess far more genes than the human genome itself. Among the countless metabolites produced by these microbes, short‑chain fatty acids (SCFAs) have emerged as key mediators of host–microbe communication. SCFAs are not directly provided by the diet; rather, they are generated by bacterial fermentation of indigestible dietary carbohydrates, primarily dietary fibre and resistant starch, in the caecum and colon (Birkeland et al. 2023; Ney et al. 2023). The three most abundant SCFAs are acetate (C2), propionate (C3) and butyrate (C4), typically present in a molar ratio of approximately 60:20:20 in the human large intestine (Birkeland et al. 2023).
By acting as energy substrates for colonocytes, as signalling molecules through specific receptors, and as regulators of gene expression, SCFAs influence not only intestinal health but also systemic metabolism, immune function, and even neurological processes. This section focuses on the fundamental biological functions of SCFAs as a bridge between the gut microbiota and host physiology, without extending into therapeutic applications.
8.1. Production of SCFAs by Gut Bacteria
SCFAs are central modulators of the mucosal immune response
Short‑chain fatty acids (acetate, propionate and butyrate) are produced by commensal bacteria in the intestine. They act on intestinal epithelial cells (tight‑junction regulation, mucin production), on peripheral immune cells (Treg differentiation, neutrophil migration, B‑cell class switching) and on macrophages (M2 polarisation). These actions help maintain intestinal barrier integrity and immune homeostasis (Ney et al. 2023, Figure 1). CC BY 4.0
The production of SCFAs depends on three interrelated factors: the availability of fermentable substrates (mainly dietary fibre), the composition and metabolic capacity of the gut microbiota, and the intestinal transit time. Major bacterial phyla involved in SCFA production include Firmicutes (particularly members of the Clostridium clusters, Faecalibacterium prausnitzii, Eubacterium spp., and Roseburia spp.) and Bacteroidetes (e.g., Bacteroides thetaiotaomicron) (Birkeland et al. 2023; Ney et al. 2023).
- Acetate is produced by many bacteria via the Wood–Ljungdahl pathway or by fermentation of pyruvate. It is the most abundant SCFA in the colon and serves as a substrate for cholesterol synthesis in the liver and for lipogenesis in peripheral tissues (Birkeland et al. 2023).
- Propionate is generated primarily by the succinate pathway (e.g., by Bacteroides spp.) and the acrylate pathway (e.g., by Veillonella spp.). Propionate is mainly taken up by the liver, where it acts as a gluconeogenic substrate (Birkeland et al. 2023; Ney et al. 2023).
- Butyrate is produced mainly by F. prausnitzii, Eubacterium rectale, Roseburia spp., and Clostridium spp. via the butyryl‑CoA:acetate CoA‑transferase pathway. Butyrate is the preferred energy source for colonocytes and plays a central role in maintaining gut barrier integrity (Ney et al. 2023; Birkeland et al. 2023).
The amount and profile of SCFAs produced are highly dependent on the type of fibre consumed. Soluble, fermentable fibres (e.g., inulin, fructo‑oligosaccharides, pectin) typically yield higher SCFA production than less fermentable insoluble fibres (e.g., cellulose) (Birkeland et al. 2023).
8.2. Butyrate as the Primary Energy Source for Colonocytes
Approximately 60‑70% of the energy requirements of colonocytes are met by the oxidation of butyrate. This energy is used to support proliferation, differentiation, and the maintenance of the intestinal epithelial barrier (Ney et al. 2023). Butyrate is taken up by colonocytes via monocarboxylate transporter 1 (MCT1) and sodium‑coupled monocarboxylate transporter 1 (SMCT1) and is then metabolised in the mitochondria through β‑oxidation to acetyl‑CoA, which enters the tricarboxylic acid (TCA) cycle (Ney et al. 2023).
By serving as the primary fuel for the colonic epithelium, butyrate supports the rapid turnover of intestinal cells and helps prevent atrophy of the gut mucosa. In addition, butyrate enhances the transcription of tight junction proteins such as claudin‑1 and occludin, thereby strengthening the intestinal barrier and reducing the translocation of luminal antigens and bacterial products into the systemic circulation (Ney et al. 2023; Birkeland et al. 2023).
8.3. SCFA Receptors on Host Cells
As introduced in Section 6, SCFAs activate several G protein‑coupled receptors, most notably GPR41 (FFAR3), GPR43 (FFAR2), and GPR109A (HCA2). These receptors are expressed not only on intestinal epithelial cells but also on immune cells, adipocytes, and enteroendocrine cells.
- GPR41 is activated by propionate > butyrate > acetate. On enteroendocrine L‑cells, GPR41 activation stimulates the release of peptide YY (PYY) and glucagon‑like peptide‑1 (GLP‑1). On adipocytes, GPR41 promotes leptin expression. In the sympathetic nervous system, GPR41 activation regulates energy expenditure (Birkeland et al. 2023; Ney et al. 2023).
- GPR43 is activated by acetate = propionate > butyrate. This receptor is abundantly expressed on immune cells, including neutrophils, monocytes, macrophages, and dendritic cells. GPR43 mediates the chemotactic effects of SCFAs on neutrophils and enhances the differentiation and suppressive function of regulatory T cells (Tregs) in the colon. In enteroendocrine cells, GPR43 also contributes to GLP‑1 and PYY secretion (Ney et al. 2023; Birkeland et al. 2023).
- GPR109A is activated by butyrate (and also by the drug niacin). It is expressed on colonic epithelial cells and on macrophages. Activation of GPR109A by butyrate suppresses colonic inflammation by promoting anti‑inflammatory signalling and by inducing the production of IL‑10 from macrophages and dendritic cells (Ney et al. 2023).
8.4. SCFAs and Intestinal Immune Homeostasis
The gut immune system must discriminate between harmless commensal bacteria and pathogenic invaders. SCFAs play a critical role in establishing and maintaining this tolerance.
Regulation of Treg cells – Butyrate and propionate promote the differentiation of naive CD4⁺ T cells into FoxP3⁺ regulatory T cells (Tregs) in the colon. This effect is mediated primarily through inhibition of histone deacetylases (HDACs), which leads to increased acetylation of histones at the FoxP3 gene locus and enhanced transcription (Ney et al. 2023). Tregs are essential for suppressing excessive immune responses to dietary antigens and commensal bacteria.
Modulation of macrophage function – Butyrate polarises intestinal macrophages toward an anti‑inflammatory (M2‑like) phenotype. Butyrate‑treated macrophages exhibit reduced production of pro‑inflammatory cytokines (e.g., TNF‑α, IL‑6, IL‑1β) and enhanced phagocytic capacity, including clearance of apoptotic neutrophils (efferocytosis) (Ney et al. 2023; Calder 2017).
Enhancement of antimicrobial peptide production – SCFAs, particularly butyrate, increase the expression of antimicrobial peptides such as cathelicidin (LL‑37) and β‑defensins by intestinal epithelial cells. These peptides help control bacterial overgrowth and protect against enteric pathogens (Ney et al. 2023).
Through these mechanisms, SCFAs contribute to a state of “physiological inflammation” in the gut that is controlled and protective rather than damaging.
8.5. SCFAs and the Gut–Brain Axis
SCFAs are also involved in communication between the gut and the central nervous system, a bidirectional pathway known as the gut–brain axis. Although the precise mechanisms are still being unravelled, several routes have been identified:
- Hormonal signalling – SCFAs, acting through GPR41 and GPR43 on enteroendocrine L‑cells, stimulate the release of GLP‑1 and PYY. These hormones act on vagal afferent neurons and on hypothalamic nuclei to reduce appetite and promote satiety (Birkeland et al. 2023).
- Direct humoral route – SCFAs, particularly acetate, can enter the systemic circulation and cross the blood–brain barrier. In the brain, acetate is taken up by astrocytes and used as an energy substrate; it also modulates neurotransmitter balance (e.g., glutamate–glutamine cycling and GABA synthesis) (Ney et al. 2023).
- Immune‑mediated signalling – By reducing intestinal permeability and lowering systemic levels of bacterial lipopolysaccharide (LPS), SCFAs attenuate low‑grade inflammation that can affect brain function (Ney et al. 2023).
These pathways allow SCFAs to influence feeding behaviour, energy balance, and even mood and cognition, although the latter effects are still under active investigation.
8.6. SCFAs and Systemic Metabolism
Beyond the gut, SCFAs have direct and indirect effects on peripheral tissues involved in energy metabolism.
Liver – Propionate and butyrate are taken up by the liver. Propionate is a substrate for gluconeogenesis, while butyrate can enter the TCA cycle. SCFA signalling through GPR43 in the liver may influence lipid and glucose metabolism, although the relative contributions of direct versus indirect effects are still being defined (Birkeland et al. 2023).
Adipose tissue – SCFAs, particularly acetate and propionate, activate GPR43 on adipocytes, leading to inhibition of lipolysis and increased fatty acid storage. This may contribute to the regulation of circulating free fatty acid levels. Acetate also promotes leptin secretion from adipocytes, which signals satiety to the brain (Birkeland et al. 2023).
Skeletal muscle – SCFAs have been reported to increase fatty acid oxidation in muscle, an effect that may be mediated in part by the activation of AMP‑activated protein kinase (AMPK). This could contribute to improved insulin sensitivity and metabolic flexibility (Birkeland et al. 2023).
8.7. SCFA Absorption and Systemic Distribution
SCFAs produced in the colonic lumen are rapidly absorbed by colonocytes. Most butyrate is used locally as an energy source, whereas acetate and propionate enter the portal circulation and are transported to the liver. The liver clears a large fraction of propionate and butyrate; acetate that escapes hepatic metabolism enters the systemic circulation and can be taken up by peripheral tissues, including muscle, heart, and brain (Birkeland et al. 2023; Ney et al. 2023).
The efficiency of SCFA absorption and metabolism is influenced by the rate of production, the expression of transporters (MCT1, SMCT1), and the metabolic state of the host. Under normal conditions, only a small percentage (typically < 5‑10%) of the SCFA produced is excreted in faeces; most is absorbed and utilised, demonstrating the efficient coupling of bacterial fermentation to host energy salvage (Birkeland et al. 2023).
8.8. Factors That Modulate SCFA Production
While a detailed discussion of dietary interventions is beyond the scope of this article, it is important to recognise that SCFA production is highly responsive to changes in diet, particularly the amount and type of dietary fibre. Diets rich in plant‑based foods (vegetables, fruits, whole grains, legumes) provide ample fermentable substrates for SCFA‑producing bacteria and are associated with higher faecal SCFA concentrations and a more diverse, resilient microbiota (Birkeland et al. 2023; Ney et al. 2023). Conversely, diets low in fibre and high in fat or protein have been associated with reduced SCFA production, lower abundance of butyrate‑producing bacteria, and impaired intestinal barrier function (Birkeland et al. 2023).
8.9. Summary: SCFAs as Multifunctional Host–Microbe Mediators
Short‑chain fatty acids are much more than metabolic waste products of bacterial fermentation. They are key signalling molecules that link the composition and activity of the gut microbiota to host physiology. By serving as the preferred energy source for colonocytes, reinforcing the intestinal barrier, modulating immune cell function, and acting through specific GPCRs on multiple cell types, SCFAs influence a wide range of biological processes, from local gut homeostasis to systemic metabolism and even brain function. The production of SCFAs is directly dependent on the availability of fermentable dietary fibre, highlighting the importance of plant‑based foods in maintaining a healthy host–microbe relationship.
9. Tissue‑Specific Biological Functions of Fatty Acids
While the previous sections have described general mechanisms by which fatty acids influence cell function — membrane structure, signalling, gene regulation — it is important to recognise that different tissues and organs have unique fatty acid compositions and utilise these molecules in specialised ways. The remarkable diversity of fatty acid functions is nowhere more evident than when comparing the nervous system, the retina, the skin, and the immune system. Each of these tissues incorporates specific fatty acids to fulfil roles that cannot be performed by others.
9.1. The Nervous System: DHA as an Essential Neurostructural Component
The mammalian brain is exceptionally rich in lipids; approximately 50‑60% of its dry weight is lipid. Among all fatty acids, docosahexaenoic acid (DHA, 22:6n-3) is the most abundant in the brain, particularly in the grey matter, where it contributes up to 40% of total fatty acids in the phospholipids of synaptic membranes, mitochondria, and synaptic vesicles (Saini & Keum 2018; Shahidi & Ambigaipalan 2018). This high concentration is evolutionarily conserved across mammals, indicating a fundamental physiological requirement.
Synaptic membrane properties: DHA has six cis‑double bonds, which confer exceptional conformational flexibility to the hydrocarbon chain. When incorporated into membrane phospholipids, DHA increases membrane fluidity, reduces the thickness of the bilayer, and facilitates the lateral diffusion of membrane proteins. These biophysical effects are critical for synaptic transmission: neurotransmitter receptors, ion channels, and vesicle fusion machinery all depend on a fluid lipid environment for optimal function (Saini & Keum 2018; Calder 2017).
Neurotransmission and plasticity: DHA influences several steps in synaptic signalling. It enhances the release of neurotransmitters such as serotonin and acetylcholine, modulates the activity of voltage‑gated ion channels, and supports long‑term potentiation (LTP) — a cellular correlate of learning and memory. DHA also promotes neurite outgrowth, synaptogenesis, and the survival of newly formed neurons (Djuricic & Calder 2021; Saini & Keum 2018).
Neuroprotective metabolites: In addition to its structural role, DHA serves as the precursor for neuroprotectin D1 (NPD1), a specialised pro‑resolving mediator that is produced in the brain by the action of 15‑lipoxygenase. NPD1 has been shown to protect neurons and glial cells from oxidative stress‑induced apoptosis, to promote the resolution of neuroinflammation, and to support the survival of photoreceptors in the retina. NPD1 also regulates the expression of anti‑apoptotic proteins (e.g., Bcl‑2) and reduces the production of pro‑inflammatory eicosanoids (Ishihara, Yoshida & Arita 2019; Saini & Keum 2018).
Consequences of DHA inadequacy: Low DHA levels in the brain have been associated with impaired cognitive performance, reduced synaptic plasticity, and accelerated age‑related decline in learning and memory. Post‑mortem studies have reported lower DHA content in the brains of individuals with Alzheimer’s disease compared to age‑matched controls (Shahidi & Ambigaipalan 2018). However, as this review is educational, it suffices to note that DHA status is strongly correlated with brain function in animal models and observational human studies, without extending to therapeutic claims.
9.2. The Retina: DHA and Visual Phototransduction
The retina contains the highest concentration of DHA of any tissue in the body. In photoreceptor outer segments — specialised organelles that capture light — DHA constitutes approximately 50% of the total fatty acids in phospholipids. This extraordinary enrichment is directly related to the function of rhodopsin, the visual pigment that initiates the phototransduction cascade (Saini & Keum 2018; Shahidi & Ambigaipalan 2018).
Biophysical role in rhodopsin activation: Rhodopsin is a G protein‑coupled receptor embedded in the disc membranes of rod photoreceptors. Upon absorption of a photon, rhodopsin undergoes a conformational change to its active form (metarhodopsin II), which then activates the G protein transducin. The kinetics of this activation depend on the fluidity of the surrounding lipid bilayer. DHA‑rich membranes allow rapid lateral diffusion of rhodopsin and transducin, facilitating the amplification of the light signal. In membranes deficient in DHA, the activation of rhodopsin is slowed and the efficiency of phototransduction is reduced (Saini & Keum 2018).
Turning over of photoreceptor membranes: Photoreceptor outer segments are continuously renewed: new discs are formed at the base of the outer segment, while older discs are shed from the tip and phagocytosed by retinal pigment epithelial (RPE) cells. DHA is recycled from shed discs and re‑used in the synthesis of new discs. This high rate of membrane turnover demands a constant supply of DHA, which must be obtained from the diet because the retina cannot synthesise DHA de novo (Shahidi & Ambigaipalan 2018).
DHA metabolites in the retina: DHA is also a substrate for the synthesis of neuroprotectin D1 (NPD1) in the RPE. NPD1 protects RPE cells from oxidative stress, promotes cell survival, and suppresses inflammatory signalling. These actions are particularly important because the retina is exposed to high levels of light‑induced oxidative stress (Ishihara et al. 2019; Saini & Keum 2018).
9.3. The Skin: Linoleic Acid and the Epidermal Barrier
The skin, particularly the stratum corneum (the outermost layer of the epidermis), has a unique lipid composition that is essential for its barrier function. Unlike the phospholipid‑rich membranes of other tissues, the stratum corneum contains a specialised lipid matrix composed of approximately 50% ceramides, 25% cholesterol, and 15% free fatty acids. Linoleic acid (LA, 18:2n-6) plays a non‑redundable structural role in this matrix (Djuricic & Calder 2021).
Ceramide structure and function: Ceramides in the stratum corneum consist of a sphingoid base linked to a long‑chain fatty acid. A significant proportion of these ceramides are acylated with linoleic acid, forming acylceramides. Linoleic acid is essential for the proper organisation of the lipid lamellae that fill the intercellular spaces of the stratum corneum. These lamellae act as the primary barrier to transepidermal water loss and to the entry of environmental irritants and pathogens (Djuricic & Calder 2021).
Unique requirement for LA: Other fatty acids, including saturated, monounsaturated, and even other PUFAs, cannot substitute for linoleic acid in this role. The specific positioning of the double bonds in LA (cis‑9, cis‑12) is required for the formation of the correct lamellar phase structure. When LA is deficient, the barrier becomes compromised, leading to increased transepidermal water loss and enhanced susceptibility to irritants — a condition that can manifest as scaly, dry skin (Djuricic & Calder 2021).
LA metabolites in skin inflammation: Once the barrier is established, LA can be released from ceramides and metabolised by 15‑lipoxygenase to 13‑hydroxyoctadecadienoic acid (13‑HODE). 13‑HODE has been reported to activate PPARγ and to exert anti‑inflammatory effects in the epidermis. Moreover, LA‑derived oxylipins may modulate the production of pro‑inflammatory eicosanoids from arachidonic acid in skin immune cells (Djuricic & Calder 2021; Berkowitz et al. 2026).
Clinical observations (educational context): Essential fatty acid deficiency in humans (rare, but historically documented in patients on fat‑free parenteral nutrition) presents with dermatitis, scaly skin, and impaired wound healing. These symptoms are rapidly reversed by the administration of linoleic acid but not by saturated or monounsaturated fatty acids, demonstrating the essential and specific role of LA in skin biology (Djuricic & Calder 2021).
9.4. The Immune System: Fatty Acids as Modulators of Leukocyte Function
Immune cells — lymphocytes, monocytes, macrophages, neutrophils, and dendritic cells — have a distinctive fatty acid composition that reflects their functional demands. As noted in Section 2, these cells are rich in arachidonic acid (ARA), typically comprising 15‑20% of their total fatty acids. The high ARA content provides a ready substrate for the production of eicosanoids upon cell activation (Innes & Calder 2018; Calder 2017).
Membrane distribution of ARA in immune cells: ARA is preferentially located at the sn‑2 position of phosphatidylcholine and phosphatidylethanolamine in immune cell membranes. Upon stimulation by pathogens, cytokines, or other inflammatory signals, phospholipase A2 is activated and releases ARA, which is then rapidly converted to prostaglandins, leukotrienes, and other eicosanoids (Innes & Calder 2018).
Incorporation of EPA and DHA into immune cells: When the diet provides EPA and DHA (e.g., from fish), these omega‑3 PUFAs are incorporated into immune cell membrane phospholipids, partially replacing ARA. This replacement has several functional consequences:
- Reduced production of ARA‑derived pro‑inflammatory eicosanoids (e.g., PGE2, LTB4).
- Increased production of less potent EPA‑derived eicosanoids (e.g., PGE₃, LTB5).
- Enhanced generation of SPMs (resolvins, protectins) from EPA and DHA.
- Altered lipid raft composition, affecting the assembly of signalling complexes such as the T‑cell receptor complex and TLR4 (Calder 2017; Innes & Calder 2018).
Effects on cytokine production: Human studies have shown that supplementation with EPA and DHA can reduce the production of pro‑inflammatory cytokines (TNF‑α, IL‑1β, IL‑6) by activated monocytes and lymphocytes, while having variable effects on the anti‑inflammatory cytokine IL‑10. These changes are associated with reduced activation of the transcription factor NF‑κB (Calder 2017; Djuricic & Calder 2021).
Macrophage polarisation: Butyrate, a short‑chain fatty acid produced by gut bacteria, has been shown to promote the polarisation of intestinal macrophages toward an anti‑inflammatory (M2‑like) phenotype, characterised by reduced production of IL‑6 and TNF‑α and enhanced phagocytic capacity (Ney et al. 2023). This effect is mediated in part through GPR109A and through inhibition of HDACs.
T cell differentiation: SCFAs, particularly butyrate and propionate, promote the differentiation of naive CD4⁺ T cells into regulatory T cells (Tregs) in the colon, an effect that depends on HDAC inhibition and enhanced FoxP3 expression. Conversely, under different cytokine milieus, SCFAs can also support the differentiation of Th1 and Th17 cells, indicating that the immunological outcome depends on the broader context (Ney et al. 2023).
9.5. Adipose Tissue: Fatty Acid Storage and Signalling
Adipose tissue is the primary site of long‑term energy storage in the form of triacylglycerols. However, it is also an active endocrine organ that secretes hormones (adipokines) and responds to fatty acid signals.
Fatty acid composition of adipose tissue: The fatty acid profile of adipose tissue triacylglycerols broadly reflects the dietary fatty acid intake over the preceding weeks to months. Thus, adipose tissue LA and ALA levels correlate with dietary intake of vegetable oils, while EPA and DHA levels reflect fish or fish oil consumption (Djuricic & Calder 2021).
PPARγ and adipocyte differentiation: As discussed in Section 7, PPARγ is the master regulator of adipogenesis. Long‑chain PUFAs, especially EPA and DHA, act as natural PPARγ ligands and promote the differentiation of pre‑adipocytes into mature, insulin‑sensitive adipocytes. This enhances the capacity of adipose tissue to store lipids in a metabolically benign form, reducing ectopic lipid deposition in the liver, muscle, and pancreas (Berkowitz et al. 2026; Calder 2017).
Adipokine secretion: The fatty acid composition of adipose tissue influences the secretion of adipokines. For example, supplementation with EPA and DHA has been reported to increase circulating adiponectin levels. Adiponectin is an insulin‑sensitising, anti‑inflammatory adipokine that also has cardioprotective properties. The effect may be mediated through PPARγ activation and through reduced inflammatory signalling within adipose tissue (Berkowitz et al. 2026; Djuricic & Calder 2022).
Fatty acid release and signalling: During fasting or exercise, stored triacylglycerols are hydrolysed, releasing free fatty acids (including LA, ARA, EPA and DHA) into the circulation. These free fatty acids can act as ligands for GPR40 and GPR120 on pancreatic β‑cells, enhancing insulin secretion, and on enteroendocrine cells, modulating incretin release (Wu, Xu & Ballantyne 2019).
9.6. The Liver: Fatty Acid Metabolism and Lipoprotein Production
The liver is the central organ for fatty acid metabolism. It takes up chylomicron remnants (rich in dietary fatty acids), synthesises fatty acids de novo from carbohydrates (lipogenesis), oxidises fatty acids for energy, and packages excess fatty acids into very‑low‑density lipoproteins (VLDL) for export to peripheral tissues.
Regulation of hepatic lipid metabolism by PUFAs: Polyunsaturated fatty acids, particularly EPA and DHA, suppress the expression of lipogenic genes in the liver by inhibiting the activation of sterol regulatory element‑binding protein‑1c (SREBP‑1c). This leads to reduced synthesis of fatty acids and triglycerides. At the same time, EPA and DHA activate PPARα, which upregulates genes involved in fatty acid oxidation (e.g., acyl‑CoA oxidase, carnitine palmitoyltransferase 1) (Djuricic & Calder 2021; Berkowitz et al. 2026).
Effect on VLDL secretion: By reducing triglyceride synthesis and increasing fatty acid oxidation, EPA and DHA reduce the availability of triglycerides for incorporation into VLDL particles. This results in lower secretion of VLDL from the liver and consequently lower plasma triglyceride levels. This effect is well documented in human studies (Calder 2017; Wu et al. 2019).
LXR and cholesterol metabolism: Linoleic acid has been shown to upregulate liver X receptor α (LXRα) expression in the liver. LXRα activation increases the expression of cholesterol 7α‑hydroxylase (CYP7A1), the rate‑limiting enzyme in bile acid synthesis. Increased bile acid production enhances the catabolism of cholesterol, reducing hepatic cholesterol content and upregulating LDL receptor expression, which lowers circulating LDL cholesterol (Djuricic & Calder 2021; Berkowitz et al. 2026).
9.7. Summary of Tissue‑Specific Functions
The examples above illustrate that the biological functions of fatty acids are not uniform across the body. Instead, each tissue has evolved to utilise specific fatty acids — DHA in the brain and retina, linoleic acid in the skin, arachidonic acid in immune cells, and various PUFAs in adipose tissue and liver — to meet its unique structural and signalling demands. This tissue‑specificity underscores the importance of adequate and balanced dietary fatty acid intake, not as a matter of calories alone, but as a requirement for the proper functioning of every organ system.
10. Interaction with the Gut Microbiota: Prebiotic Effects of Polyunsaturated Fatty Acids
The relationship between dietary fatty acids and the gut microbiota is bidirectional. While short‑chain fatty acids (SCFAs) produced by bacterial fermentation influence host physiology (as discussed in Section 8), long‑chain polyunsaturated fatty acids (PUFAs) — particularly the omega‑3 family — can themselves modify the composition, diversity, and metabolic activity of the gut microbial community. This effect has been described as a “prebiotic‑like” action, because certain PUFAs selectively promote the growth of bacteria that are associated with health benefits (Birkeland et al. 2023; Ney et al. 2023).
10.1. Omega‑3 PUFAs and Gut Microbial Composition
Several studies in rodents and humans have demonstrated that supplementation with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) alters the relative abundance of specific bacterial taxa. Key observations include:
- Increased abundance of beneficial genera – Omega‑3 PUFA supplementation has been associated with higher proportions of Bifidobacterium, Lactobacillus, Roseburia, Faecalibacterium prausnitzii, and Coprococcus in the gut. These bacteria are known producers of butyrate and other SCFAs and are generally considered markers of a healthy microbiota (Birkeland et al. 2023; Ney et al. 2023).
- Decreased abundance of potentially harmful genera – Conversely, omega‑3 PUFAs have been shown to reduce the abundance of Collinsella (a genus associated with fatty liver disease and atherosclerosis) and certain pathogenic Enterobacteriaceae (Birkeland et al. 2023).
- Increased microbial diversity – Higher dietary intake of omega‑3 PUFAs or higher blood levels of EPA and DHA have been correlated with increased alpha diversity (a measure of the number and evenness of species) of the gut microbiota. Reduced diversity is a hallmark of dysbiosis and is associated with various metabolic and inflammatory disorders (Birkeland et al. 2023).
The magnitude and direction of these changes depend on the dose and duration of omega‑3 exposure, the baseline composition of the microbiota, and the background diet (Birkeland et al. 2023).
10.2. Mechanisms of Microbiota Modulation by PUFAs
The mechanisms by which dietary long‑chain PUFAs influence gut bacterial populations are not fully understood, but several possibilities have been proposed:
- Direct antimicrobial effects – PUFAs, especially when free (non‑esterified), can incorporate into bacterial membranes, alter membrane fluidity, increase permeability, and inhibit bacterial growth. Gram‑positive bacteria are generally more sensitive to the antibacterial effects of PUFAs than Gram‑negative bacteria, because Gram‑negative bacteria possess an outer lipopolysaccharide layer that restricts access (Ney et al. 2023).
- Changes in the intestinal environment – PUFAs can modify the luminal pH, bile acid composition, and mucus secretion, creating a niche that favours certain bacterial species over others. For example, omega‑3 PUFAs have been reported to increase the production of antimicrobial peptides (e.g., cathelicidin) by intestinal epithelial cells, which may selectively suppress pathogenic bacteria (Ney et al. 2023).
- Indirect effects through host metabolism – Omega‑3 PUFAs reduce intestinal inflammation, lower oxidative stress, and improve gut barrier function. A less inflamed intestinal environment may be more hospitable to beneficial, SCFA‑producing bacteria and less supportive of pro‑inflammatory or mucolytic species (Birkeland et al. 2023).
- Cross‑feeding interactions – When PUFAs are not completely absorbed in the small intestine, they reach the colon and may be metabolised by certain bacteria, producing intermediates that serve as substrates for other beneficial bacteria (syntrophic cross‑feeding) (Birkeland et al. 2023).
10.3. Human Intervention Studies
Randomised controlled trials in humans have provided evidence for the prebiotic effects of omega‑3 PUFAs, although the results are not entirely consistent across studies.
- Increased Bifidobacteria – Several trials have reported that fish oil supplementation (providing 2‑4 g EPA+DHA per day for 6‑12 weeks) significantly increased the abundance of Bifidobacterium in the faeces of healthy adults and in patients with metabolic syndrome. This effect was often accompanied by an increase in faecal SCFA concentrations (Birkeland et al. 2023).
- Reduced Collinsella – A 6‑week intervention with omega‑3 capsules (165 mg EPA + 110 mg DHA daily) in healthy adults resulted in a significant decrease in the abundance of Collinsella and a concurrent increase in Bacteroides and Coprococcus. Coprococcus abundance was positively correlated with faecal isobutyric acid and negatively correlated with serum VLDL‑triglycerides (Birkeland et al. 2023).
- Variability of responses – Not all studies have observed significant changes in gut microbiota composition following omega‑3 supplementation. This variability may be explained by differences in the dose and formulation of omega‑3, the duration of intervention, the baseline diet, and individual differences in the gut microbial community (Birkeland et al. 2023).
10.4. Interaction Between Omega‑3 PUFAs, Microbiota and Host Metabolism
The prebiotic effects of omega‑3 PUFAs may contribute to their beneficial metabolic actions. For example:
- Enhanced SCFA production – By increasing the abundance of butyrate‑producing bacteria (e.g., F. prausnitzii, Roseburia), omega‑3 PUFAs can augment the colonic production of butyrate, which then strengthens the intestinal barrier and reduces systemic inflammation (Birkeland et al. 2023; Ney et al. 2023).
- Reduced endotoxaemia – A healthier microbiota with increased numbers of Bifidobacterium and other barrier‑protective bacteria reduces the translocation of lipopolysaccharide (LPS) from the gut lumen into the portal and systemic circulation. This attenuates metabolic endotoxaemia, a low‑grade inflammatory state that contributes to insulin resistance and hepatic steatosis (Birkeland et al. 2023).
- Modulation of bile acid metabolism – The gut microbiota deconjugates and modifies primary bile acids into secondary bile acids. Omega‑3 PUFAs can alter the composition of the bile acid pool, which in turn influences lipid absorption and signalling through the nuclear receptor FXR (farnesoid X receptor) (Birkeland et al. 2023).
10.5. Prebiotic Potential of Other Fatty Acids
While most research has focused on omega‑3 PUFAs, other fatty acids may also influence the gut microbiota:
- Linoleic acid (LA) – High‑LA diets have been shown in animal models to induce dysbiosis, reduce microbial diversity, and increase the abundance of pro‑inflammatory taxa. However, in humans, the effects are less clear and may depend on the overall fat composition and the presence of other dietary components (Berkowitz et al. 2026).
- Conjugated linoleic acid (CLA) – Certain bacteria (e.g., Lactobacillus spp.) can convert LA to CLA, which has been associated with anti‑obesity and anti‑inflammatory effects in animal studies. This transformation represents another example of host–microbe co‑metabolism of fatty acids (Berkowitz et al. 2026).
- Short‑chain fatty acids themselves – Although SCFAs are products rather than modulators of the microbiota, they can influence bacterial growth. For example, butyrate is used as an energy source by many colonic bacteria, and its presence can alter the competitive dynamics within the microbial community (Ney et al. 2023).
10.6. Methodological Considerations
Studying the interaction between dietary fatty acids and the gut microbiota in humans faces several challenges:
- High inter‑individual variability – The composition of the gut microbiota is highly personalised, making it difficult to detect consistent changes across a small number of participants.
- Confounding by diet – Most human studies rely on self‑reported dietary intake, which is imprecise. Moreover, diets high in omega‑3 PUFAs are often also rich in other components (e.g., fibre, vitamins) that independently affect the microbiota.
- Duration of intervention – The microbiota can respond rapidly (within days) to dietary changes, but long‑term stability of new microbial states may require weeks to months of sustained dietary modification.
- Analytical limitations – 16S rRNA sequencing provides information on taxonomy but not on function. Metagenomic and metabolomic approaches are more informative but are also more expensive and technically demanding (Birkeland et al. 2023).
10.7. Summary: Fatty Acids as Prebiotic Agents
Long‑chain polyunsaturated fatty acids, particularly EPA and DHA from fish oil, can modulate the composition and activity of the gut microbiota. In human studies, omega‑3 supplementation has been associated with increased abundance of beneficial genera such as Bifidobacterium and Lactobacillus, increased microbial diversity, and reduced levels of potentially harmful bacteria such as Collinsella. These changes are accompanied by increased production of SCFAs, reduced intestinal permeability, and attenuated metabolic endotoxaemia. Thus, the beneficial effects of omega‑3 PUFAs on host metabolism may be mediated, at least in part, through their prebiotic action on the gut microbiota. This emerging area of research highlights the complex interplay between dietary fats, the microbial ecosystem of the gut, and host physiology.
11. Fatty Acids as Energy Substrates and Metabolic Flexibility
Fatty acids are one of the most energy‑dense molecules in the body, yielding approximately 37 kJ (9 kcal) per gram when fully oxidised, compared to about 17 kJ (4 kcal) per gram for carbohydrates or proteins. This high energy density makes fatty acids the preferred fuel for many tissues during periods of fasting, prolonged exercise, or low carbohydrate availability. However, the biological function of fatty acids as energy substrates extends beyond simple caloric provision; the type, chain length, and degree of unsaturation of fatty acids influence how efficiently they are oxidised, how they modulate mitochondrial function, and how they interact with other fuel sources. The ability of a cell or organism to switch between different energy substrates (glucose, fatty acids, ketone bodies) in response to changing physiological conditions is termed metabolic flexibility (Berkowitz et al. 2026; Djuricic & Calder 2022).
11.1. β‑Oxidation: The Primary Pathway for Fatty Acid Catabolism
The major pathway for the oxidation of fatty acids is mitochondrial β‑oxidation. This process occurs in the mitochondrial matrix and involves four recurring reactions that sequentially remove two‑carbon units as acetyl‑CoA, which then enters the tricarboxylic acid (TCA) cycle for complete oxidation to carbon dioxide and water. The reducing equivalents (NADH and FADH2) generated by β‑oxidation and the TCA cycle feed into the electron transport chain, driving ATP synthesis (Berkowitz et al. 2026).
Activation and transport: Before oxidation, free fatty acids are activated to fatty acyl‑CoA by acyl‑CoA synthetase (thiokinase) in the cytosol. Long‑chain acyl‑CoA cannot cross the inner mitochondrial membrane directly; it must be transported via the carnitine shuttle. Carnitine palmitoyltransferase 1 (CPT1), located on the outer mitochondrial membrane, converts acyl‑CoA to acylcarnitine, which is then transported across the inner membrane by the carnitine‑acylcarnitine translocase. Inside the matrix, carnitine palmitoyltransferase 2 (CPT2) reconverts acylcarnitine to acyl‑CoA, making it available for β‑oxidation (Berkowitz et al. 2026).
Regulation of β‑oxidation: CPT1 is the rate‑limiting enzyme of fatty acid oxidation and is inhibited by malonyl‑CoA, the first intermediate in fatty acid synthesis. This reciprocal regulation ensures that fatty acid synthesis and oxidation do not occur simultaneously at high rates. Hormonal signals (e.g., glucagon, adrenaline) and the cellular energy state (low ATP, high AMP) activate β‑oxidation, while insulin suppresses it (Berkowitz et al. 2026).
11.2. Tissue‑Specific Utilisation of Fatty Acids
Different tissues have evolved distinct capacities and preferences for fatty acid oxidation, reflecting their metabolic roles.
Heart – The healthy heart derives approximately 60‑80% of its ATP from fatty acid oxidation, with the remainder from glucose, lactate, and ketone bodies. Fatty acids are the preferred fuel because they yield more ATP per molecule than glucose, and the heart has a high oxygen extraction ratio. However, excessive fatty acid oxidation can impair cardiac efficiency under certain conditions (Berkowitz et al. 2026).
Skeletal muscle – Muscle fibres vary in their reliance on fatty acids. Type I (slow‑twitch, oxidative) fibres have abundant mitochondria and high oxidative capacity, readily using fatty acids during rest and low‑intensity exercise. Type II (fast‑twitch, glycolytic) fibres rely more on glucose. During prolonged moderate exercise, muscle shifts from carbohydrate to fatty acid oxidation to preserve glycogen stores (Berkowitz et al. 2026).
Liver – The liver oxidises fatty acids for its own energy needs but also exports fatty acids as VLDL‑triglycerides. During fasting, the liver increases fatty acid oxidation and ketogenesis, producing ketone bodies (acetoacetate, β‑hydroxybutyrate) that serve as an alternative fuel for the brain and other extrahepatic tissues (Djuricic & Calder 2022).
Adipose tissue – While adipocytes store fatty acids as triacylglycerols, they also possess the capacity for fatty acid oxidation, particularly during fasting or when stimulated by hormones such as catecholamines. However, the primary function of white adipose tissue is storage rather than oxidation (Berkowitz et al. 2026).
Brain – Under normal fed conditions, the brain relies almost exclusively on glucose. During prolonged fasting or very low‑carbohydrate diets, the brain adapts to use ketone bodies derived from hepatic fatty acid oxidation. The brain itself does not oxidise long‑chain fatty acids to any significant extent because fatty acids do not cross the blood–brain barrier efficiently, although endothelial cells and astrocytes can metabolise some fatty acids (Berkowitz et al. 2026).
11.3. Metabolic Flexibility and Its Determinants
Metabolic flexibility refers to the ability to switch between substrates (glucose and fatty acids) in response to changes in nutrient availability, hormonal signals, and energy demand. A metabolically flexible cell can oxidise fatty acids when glucose is scarce and suppress fatty acid oxidation when glucose is abundant. This adaptability is essential for maintaining energy homeostasis and preventing toxic accumulation of lipid intermediates (Berkowitz et al. 2026).
Determinants of metabolic flexibility include:
- Insulin sensitivity – In insulin‑sensitive individuals, insulin suppresses fatty acid release from adipose tissue (anti‑lipolytic effect) and promotes glucose uptake and oxidation in muscle. In insulin‑resistant states, adipose tissue lipolysis is less suppressed, leading to elevated circulating free fatty acids, which drive ectopic lipid deposition and further insulin resistance (Berkowitz et al. 2026).
- Mitochondrial function – Efficient fatty acid oxidation requires a healthy mitochondrial network. Impaired mitochondrial oxidative capacity reduces the ability to switch to fat oxidation, contributing to the accumulation of fatty acid intermediates (e.g., diacylglycerols, ceramides) that interfere with insulin signalling (Berkowitz et al. 2026; Ali et al. 2024).
- Peroxisome proliferator‑activated receptors (PPARs) – PPARα and PPARδ are key transcriptional regulators of genes involved in fatty acid uptake, activation, and oxidation. Activation of these receptors by fatty acids (especially EPA and DHA) enhances oxidative capacity and promotes metabolic flexibility (Djuricic & Calder 2022; Calder 2017).
- AMP‑activated protein kinase (AMPK) – AMPK is a cellular energy sensor that is activated when ATP levels fall (high AMP/ATP ratio). Once activated, AMPK stimulates fatty acid oxidation (by inhibiting acetyl‑CoA carboxylase and reducing malonyl‑CoA, thereby relieving CPT1 inhibition) and increases glucose uptake. Many fatty acids, including EPA and DHA, have been shown to activate AMPK (Berkowitz et al. 2026).
11.4. Influence of Fatty Acid Composition on Oxidation
Not all fatty acids are oxidised at the same rate or with the same efficiency. Key factors include chain length and degree of unsaturation.
Short‑ and medium‑chain fatty acids – SCFAs (C2‑C4) and medium‑chain fatty acids (MCFAs, C6‑C12) can diffuse across the mitochondrial membrane without the carnitine shuttle and are rapidly oxidised. They are less likely to be stored as triacylglycerols. This property is the basis for the use of MCFAs in certain nutritional formulations.
Long‑chain saturated fatty acids – Long‑chain SFAs (e.g., palmitate, C16:0; stearate, C18:0) require the carnitine shuttle for transport into mitochondria. Their oxidation is regulated by CPT1 and is sensitive to malonyl‑CoA levels. High intakes of long‑chain SFAs, when combined with high carbohydrate intake, can lead to their accumulation and the formation of potentially toxic intermediates (Berkowitz et al. 2026).
Monounsaturated and polyunsaturated fatty acids – MUFAs (e.g., oleate, C18:1) and PUFAs (e.g., linoleate, α‑linolenate, EPA, DHA) are generally oxidised more rapidly than SFAs of the same chain length. The presence of double bonds increases the susceptibility of the fatty acid to mitochondrial oxidation. Moreover, PUFAs activate PPARα and AMPK, thereby upregulating the entire oxidative machinery (Calder 2017; Berkowitz et al. 2026).
11.5. Cardiolipins and Mitochondrial Function
A specialised class of phospholipids called cardiolipins is found almost exclusively in the inner mitochondrial membrane, where they play a critical role in maintaining the structure and function of the electron transport chain. Cardiolipins are unique because they contain four fatty acyl chains. The predominant fatty acid in cardiolipins is linoleic acid (18:2n-6) in most mammalian tissues (Ali et al. 2024; Berkowitz et al. 2026).
Remodelling of cardiolipins: The fatty acid composition of cardiolipins is not static; it is continuously remodelled by the action of cardiolipin‑specific acyltransferases. When the availability of LA is limited, or when there is excessive oxidative stress, LA in cardiolipins can be replaced by other fatty acids, particularly long‑chain PUFAs with four or more double bonds. Such remodelling alters the biophysical properties of cardiolipins and can affect the activity of electron transport chain complexes (especially Complexes III and IV) and the stability of supercomplexes (Ali et al. 2024).
Oxidation of cardiolipin LA: Cardiolipins are highly susceptible to oxidative damage because of the high content of PUFAs. Oxidised cardiolipins can trigger the release of pro‑apoptotic factors (e.g., cytochrome c) from mitochondria, contributing to cell death pathways. Thus, the composition of cardiolipin fatty acids is a determinant of mitochondrial resilience to oxidative stress (Ali et al. 2024).
11.6. Fatty Acids and Ketogenesis
During periods of fasting, carbohydrate restriction, or prolonged exercise, the liver converts acetyl‑CoA derived from fatty acid β‑oxidation into ketone bodies: acetoacetate, β‑hydroxybutyrate, and acetone. Ketone bodies are water‑soluble and can be transported in the blood to extrahepatic tissues, where they are reconverted to acetyl‑CoA and oxidised for ATP production (Djuricic & Calder 2022).
Conditions favouring ketogenesis: When carbohydrate availability is low, oxaloacetate (a TCA cycle intermediate) is depleted, limiting the entry of acetyl‑CoA into the TCA cycle. The surplus acetyl‑CoA is then diverted to ketogenesis. The availability of fatty acids (from adipose tissue lipolysis) is the primary driver of ketone body production.
Role of PUFAs in ketogenesis: Omega‑3 PUFAs have been shown to enhance ketogenesis in the liver, possibly through activation of PPARα and increased expression of enzymes involved in fatty acid oxidation and ketone body synthesis (e.g., HMG‑CoA synthase 2). This effect may be relevant during fasting or low‑carbohydrate diets, but the magnitude varies with species and experimental conditions (Djuricic & Calder 2022).
11.7. Fatty Acid Oxidation and Redox Balance
The oxidation of fatty acids generates not only ATP but also reactive oxygen species (ROS) as by‑products of the electron transport chain. The rate of ROS production depends on the fatty acid being oxidised and the efficiency of the electron transport chain.
Double bonds and ROS: PUFAs are more prone to peroxidation than SFAs or MUFAs because the bis‑allylic hydrogens present between double bonds are highly susceptible to abstraction by free radicals. When PUFAs are incorporated into mitochondrial membranes or when they are oxidised, there is a potential for increased lipid peroxidation and oxidative stress if antioxidant defences are inadequate (Ali et al. 2024).
Uncoupling proteins (UCPs): UCP2 and UCP3 are expressed in mitochondria of several tissues. These proteins can dissipate the proton gradient, reducing ATP synthesis but also decreasing ROS production. Fatty acids, particularly PUFAs, have been shown to activate UCPs, possibly as a feedback mechanism to limit oxidative damage during periods of high fatty acid flux (Berkowitz et al. 2026).
11.8. Metabolic Flexibility in Health
Maintaining metabolic flexibility is essential for health. A metabolically flexible individual can efficiently switch between fuels, maintaining stable blood glucose levels during fasting and rapidly clearing postprandial triglycerides. Loss of metabolic flexibility (also called metabolic inflexibility) is a hallmark of obesity, type 2 diabetes, and the metabolic syndrome. It is characterised by impaired suppression of fatty acid oxidation after a carbohydrate‑rich meal (leading to continued lipid use despite abundant glucose) and, conversely, impaired ability to increase fatty acid oxidation during fasting (leading to ectopic lipid accumulation) (Berkowitz et al. 2026).
Contribution of fatty acid composition: Diets rich in PUFAs, particularly omega‑3 PUFAs, have been associated with improved metabolic flexibility in animal models and, to some extent, in human studies. Proposed mechanisms include activation of PPARα and PPARδ, upregulation of mitochondrial biogenesis, enhancement of CPT1 activity, and reduction of inflammatory signalling that interferes with insulin action (Djuricic & Calder 2022; Berkowitz et al. 2026).
11.9. Summary: Fatty Acids as Versatile Energy Substrates
Fatty acids are a major source of energy for the body, particularly for the heart, skeletal muscle during prolonged exercise, and the liver during fasting. Their oxidation is tightly regulated at multiple levels, including transport into mitochondria (CPT1), hormonal control (insulin, glucagon, adrenaline), and transcriptional regulation (PPARs, AMPK). The efficiency and consequences of fatty acid oxidation depend on chain length, degree of unsaturation, and the cellular context. Metabolic flexibility — the ability to switch between glucose and fatty acids as fuels — is a key determinant of metabolic health. Fatty acids, especially PUFAs, influence metabolic flexibility through their effects on signalling pathways, gene expression, and mitochondrial function. Thus, beyond their role as passive energy stores, fatty acids actively shape how cells and organisms respond to changing nutrient availability.
12. Conclusion
Fatty acids are far more than passive energy reserves or mere structural components of cell membranes. As this review has sought to demonstrate, they are dynamic, multifunctional molecules that actively participate in virtually every aspect of cellular physiology. From the biophysical properties of the lipid bilayer to the intricate networks of cell signalling and gene regulation, fatty acids shape the way cells respond to their environment, communicate with one another, and maintain homeostasis.
The journey from dietary essential fatty acids — linoleic acid (LA) and α‑linolenic acid (ALA) — to their long‑chain polyunsaturated derivatives (arachidonic acid, EPA and DHA) illustrates the elegant interplay between nutrition and endogenous metabolism (Djuricic & Calder 2021; Saini & Keum 2018). These conversions are not merely academic; they determine the availability of substrates for the production of eicosanoids, oxylipins, and specialised pro‑resolving mediators (SPMs) — families of signalling molecules that regulate inflammation, vascular tone, and tissue repair (Innes & Calder 2018; Ishihara, Yoshida & Arita 2019; Calder 2017).
The discovery that omega‑3 fatty acids give rise to resolvins, protectins and maresins has fundamentally changed our understanding of how inflammation is terminated. Rather than a passive “fading away”, the resolution of inflammation is now recognised as an actively programmed process involving specific mediators, receptors and cellular responses (Ishihara et al. 2019). This insight places fatty acids at the centre of host defence and tissue regeneration, far beyond their traditional roles.
The membrane is not an inert container but a dynamic signalling platform. The fatty acid composition of membrane phospholipids — particularly the balance between arachidonic acid, EPA and DHA — influences lipid raft organisation, receptor clustering, and the activation of intracellular signalling cascades (Calder 2017; Wu, Xu & Ballantyne 2019). By modifying membrane properties, fatty acids can alter the sensitivity of cells to external stimuli without changing the expression of a single gene.
Receptor‑mediated sensing of fatty acids adds another layer of complexity. G protein‑coupled receptors such as GPR40, GPR120, GPR41 and GPR43 allow cells to detect changes in extracellular fatty acid concentrations within seconds to minutes, triggering rapid homeostatic adjustments (Birkeland et al. 2023; Ney et al. 2023; Berkowitz et al. 2026). These systems are complemented by the slower but more sustained actions of nuclear receptors, particularly the PPAR family, which regulate the expression of genes involved in lipid and glucose metabolism, adipocyte differentiation, and inflammation (Calder 2017; Djuricic & Calder 2022).
The gut microbiota adds yet another dimension. Short‑chain fatty acids — acetate, propionate and butyrate — produced by bacterial fermentation of dietary fibre, are not mere waste products but essential signals that link microbial activity to host metabolism, immune function and even brain function (Birkeland et al. 2023; Ney et al. 2023). Butyrate, in particular, serves as the primary fuel for colonocytes and strengthens the intestinal barrier, while propionate and acetate influence gluconeogenesis, lipogenesis and appetite regulation. The ability of long‑chain omega‑3 PUFAs to modulate the composition of the gut microbiota — increasing beneficial genera such as Bifidobacterium and reducing pro‑inflammatory taxa — represents an emerging prebiotic mechanism that may contribute to their broader biological effects (Birkeland et al. 2023).
Tissue specialisation is another recurring theme. The brain and retina have evolved to rely on DHA for synaptic transmission, neuroplasticity and phototransduction (Saini & Keum 2018; Shahidi & Ambigaipalan 2018). The skin requires linoleic acid as an indispensable component of the epidermal barrier (Djuricic & Calder 2021). Immune cells are enriched in arachidonic acid, which provides the substrate for rapid eicosanoid production upon activation (Innes & Calder 2018). These examples underscore that a “one‑size‑fits‑all” view of fatty acid function is inadequate; each tissue has unique requirements that must be met by a specific fatty acid profile.
Finally, fatty acids are major energy substrates. Their mitochondrial β‑oxidation powers the heart, skeletal muscle during prolonged exercise, and the liver during fasting. The efficiency of this process depends on chain length and unsaturation, and it is tightly integrated with glucose metabolism through mechanisms such as the Randle cycle and the regulation of CPT1 by malonyl‑CoA (Berkowitz et al. 2026). Metabolic flexibility — the ability to switch between fuels — is a hallmark of health, and fatty acid composition influences this capacity through effects on PPARs, AMPK and mitochondrial function.
Throughout this review, we have deliberately avoided clinical recommendations and therapeutic claims. The aim has been to provide an educational overview of the fundamental biological functions of fatty acids — from molecules to cells, from tissues to the whole organism. The literature is clear: fatty acids are not inert calories to be simply counted and restricted. They are active participants in the molecular dialogue that sustains life. Understanding this complexity is not only intellectually satisfying but also essential for any meaningful discussion of nutrition and health.
Future research will undoubtedly uncover new mediators, additional receptors, and previously unrecognised interactions between dietary fats and the gut microbiome. The emerging field of lipidomics — the comprehensive analysis of lipid species in biological samples — promises to reveal how specific fatty acid signatures correlate with physiological states and how they are remodelled by diet. Such knowledge will continue to refine our appreciation of why the type, not just the amount, of fat matters.
In summary, the biological functions of fatty acids span structural, metabolic, signalling, and regulatory roles that are essential for normal physiology. They are key determinants of membrane architecture, precursors of potent lipid mediators, ligands for membrane and nuclear receptors, modulators of the gut microbiota, and versatile energy substrates. To view them only as a source of calories is to miss the richness of their biology — a richness that this review has attempted to capture.
References
- Ali, Z., Al-Ghouti, M.A., Abou-Saleh, H. & Rahman, M.M. (2024) ‘Unraveling the Omega-3 Puzzle: Navigating Challenges and Innovations for Bone Health and Healthy Aging’, Marine Drugs, 22(10), 446. DOI: 10.3390/md22100446 PubMed
- Berkowitz, L., Araneda, P., Cofré, G., Sara, D., Olsen, M., Urzúa, I., Pérez, D. & Rigotti, A. (2026) ‘The controversial role of linoleic acid in cardiometabolic health: from molecular pathways to human studies’, Frontiers in Nutrition, 12, 1728865. DOI: 10.3389/fnut.2025.1728865 PubMed
- Birkeland, E., Gharagozlian, S., Valeur, J. & Aas, A.-M. (2023) ‘Short-chain fatty acids as a link between diet and cardiometabolic risk: a narrative review’, Lipids in Health and Disease, 22, 40. DOI: 10.1186/s12944-023-01803-5 PubMed
- Blomhoff, R., Andersen, R., Arnesen, E.K., Christensen, J.J., Eneroth, H., Erkkola, M., Gudanaviciene, I., Halldórsson, Þ.I., Høyer‑Lund, A., Lemming, E.W., Meltzer, H.M., Pitsi, T., Schwab, U., Siksna, I., Þórsdóttir, I. & Trolle, E. (2023) Nordic Nutrition Recommendations 2023. Copenhagen: Nordic Council of Ministers. DOI: 10.6027/nord2023-003
- Calder, P.C. (2017) ‘Omega-3 fatty acids and inflammatory processes: from molecules to man’, Biochemical Society Transactions, 45(5), 1105-1115. DOI: 10.1042/BST20160474 PubMed
- Djuricic, I. & Calder, P.C. (2021) ‘Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021’, Nutrients, 13(7), 2421. DOI: 10.3390/nu13072421 PubMed
- Djuricic, I. & Calder, P.C. (2022) ‘Polyunsaturated fatty acids and metabolic health: novel insights’, Current Opinion in Clinical Nutrition and Metabolic Care, 25(6), 436-442. DOI: 10.1097/MCO.0000000000000865 PubMed
- Innes, J.K. & Calder, P.C. (2018) ‘Omega-6 fatty acids and inflammation’, Prostaglandins, Leukotrienes and Essential Fatty Acids, 132, 41-48. DOI: 10.1016/j.plefa.2018.03.004 PubMed
- Ishihara, T., Yoshida, M. & Arita, M. (2019) ‘Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis’, International Immunology, 31(9), 559-567. DOI: 10.1093/intimm/dxz001 PubMed
- Mozaffarian, D. (2016) ‘Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review’, Circulation, 133(2), 187-225. DOI: 10.1161/CIRCULATIONAHA.115.018585 PubMed
- Ney, L.-M., Wipplinger, M., Grossmann, M., Engert, N., Wegner, V.D. & Mosig, A.S. (2023) ‘Short chain fatty acids: key regulators of the local and systemic immune response in inflammatory diseases and infections’, Open Biology, 13, 230014. DOI: 10.1098/rsob.230014 PubMed
- Rodriguez, D., Lavie, C.J., Elagizi, A. & Milani, R.V. (2022) ‘Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health’, Nutrients, 14(23), 5146. DOI: 10.3390/nu14235146 PubMed
- Saini, R.K. & Keum, Y.-S. (2018) ‘Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance - A review’, Life Sciences, 203, 255-267. DOI: 10.1016/j.lfs.2018.04.049 PubMed
- Shahidi, F. & Ambigaipalan, P. (2018) ‘Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits’, Annual Review of Food Science and Technology, 9, 345-381. DOI: 10.1146/annurev-food-111317-095850 PubMed
- Simopoulos, A.P. (2016) ‘An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity’, Nutrients, 8(3), 128. DOI: 10.3390/nu8030128 PubMed
- Wali, J.A., Jarzebska, N., Raubenheimer, D., Simpson, S.J., Rodionov, R.N. & O’Sullivan, J.F. (2020) ‘Cardio-Metabolic Effects of High-Fat Diets and Their Underlying Mechanisms-A Narrative Review’, Nutrients, 12(5), 1505. DOI: 10.3390/nu12051505 PubMed
- Wu, H., Xu, L. & Ballantyne, C.M. (2019) ‘Dietary and Pharmacological Fatty Acids and Cardiovascular Health’, The Journal of Clinical Endocrinology & Metabolism, 105(4), 1030-1045. DOI: 10.1210/clinem/dgz174 PubMed
